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Osteoarthritis is one of the most common causes of disability in adults in America. It is a
progressive and degenerative disease where the articular cartilage is broken down and lost from
the surfaces of bones causing chronic pain and swelling in the joints, and currently has no cure.
The most commonly osteoarthritis starts from a focal lesion on the cartilage surface, which will
expand on the surface and downwards through the thickness of the tissue. The current gold
standard for correcting cartilage focal lesions is the osteochondral autograft/allograft
transplantation (OAT), which replaces the defect with a fresh osteochondral graft. The main
limiting factor for using the OAT comes from the limited number of autograft and allografts that
are available for implantation. To address the concern of graft availability, this study will look at
the development of a porcine osteochondral xenograft (OCXG). The first aim of this research is
to establish a decellularization protocol that will remove the antigens and cellular debris, which
are the leading causes of graft rejection when implanting animal tissue in humans. The second
aim of this study is restoring the mechanical strength of the OCXG that was lost during the
decellularization process through crosslinking the tissue using genipin and epigallocatechin
gallate (EGCG). The third aim is comparing the performance of the complete crosslinked

OCXG at different degrees of crosslinking in a long-term goat animal model. The final aim is an
alternative way to correct focal lesions through the development of an injectable collagen
stabilizing treatment with genipin and punicalagin that will slow or stop the growth of a lesion
and prevent osteoarthritis.
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CHAPTER I
INTRODUCTION
1.1

Arthritis
One of the largest growing physical disabilities facing the United States today is arthritis,

a broad term for any condition of the joint that causes swelling, pain, stiffness, and decreased
range of motion. Currently no type of arthritis has a cure, and treatment relies on symptom
management. The Centers for Disease Control and Prevention (CDC) has conservatively
estimated that 22.7% (54.4 million) of all U.S. adults have been diagnosed with some form of
arthritis by their doctor between 2013 and 2015 and of those 54.4 million people, 43.5% (23.1
million) reported that arthritis significantly impacted their everyday activities1,2. A study by
Jafarzadeh and Felson determined that the 2015 CDC statistics underestimated arthritis
prevalence and that an estimate of symptomatic and doctor diagnosed arthritis was closer to
36.8% (91.2 million) of the adult population3. The most concerning statistic in both studies is
the prevalence of arthritis effecting a higher number of adults between the ages of 18-65 years
old which makes up 75% of the total cases. These statistics contradicts the bias that generally
arthritis only affects the elderly population. The economic impact to the arthritis patient in 2013
was on average a $2,117 increase in medical costs and an earnings decrease of $4,040 when
compared to a healthy adult, which resulted in a total medical and earnings loss of $304 billion in
the United States2,4. The most common form of arthritis is osteoarthritis (OA), which is
estimated to affect 30.8 million Americans and is the leading cause of disability in adults2,5,6.
1

1.2

Osteoarthritis
Osteoarthritis is a progressive and degenerative disease in which the articular cartilage

lining the bones of a joint is damaged causing the cartilage to break down over time. Cartilage’s
lack of vascularization severely limits the tissue’s ability to repair damage and regenerate lost
tissue. The onset of osteoarthritis happens when enough cartilage has broken down causing
chronic pain and joint swelling. The most common form of osteoarthritis is primary OA which
develops from everyday wear and tear of cartilage over a person’s lifetime, and it often affects
elderly adults. The alternative progression of osteoarthritis is known as secondary OA; which
differs from primary OA in that it is caused by a specific event such as traumatic injury, disease,
obesity, etc. , and is known to affect younger patients7. In both cases, as the disease progresses
OA causes destruction of the subchondral bone; growth of bone spurs in the joint; inflammation
of the synovium; deterioration of ligaments and tendons; and the destruction of articular cartilage
in the joint.
1.3

Articular Cartilage
To better understand osteoarthritis, a further understanding of articular cartilage anatomy

is key. Articular cartilage is a highly specialized connective tissue with a smooth, white
appearance that lines the articular surface of bones in synovial joints. It serves to absorb shock,
smooth movement, distribute loads, lubricate, and decrease friction within joints. Cartilage
differs from most tissue because it lacks blood vessels, nerves, and lymphatics. It is composed
of specialized cells known as chondrocytes and a dense extracellular matrix (ECM) comprised of
collagen, proteoglycans, and water.

2

1.3.1

Composition
Chondrocytes in articular cartilage make up about 2% of the total tissue mass and are

naturally spherical cells that develop, maintain, and repair the ECM by synthesizing type II
collagen, proteoglycans, non-collagenous proteins, and enzymes that degrade the matrix. They
form a microenvironment around themselves known as a lacuna, which traps the cell inside and
anchors them to the ECM. As a result, chondrocytes have low direct cell-to-cell interactions and
rely on the use of mostly paracrine growth factors and mechanical stimuli to direct their actions.
In addition, chondrocytes depend on anaerobic metabolism and receive nutrition through a
double diffusion barrier. As mentioned previously, the chondrocytes maintain the ECM by
creating its two components: collagen and proteoglycans. Collagen acts as the structural
backbone for the ECM, making up 10-20% of the articular cartilage mass, with type II collagen
making up 85-95% of the total collagen. The role of collagen in the ECM is to give articular
cartilage structure and allow it to resist sheer, tensile, and compressive forces. Alternatively,
proteoglycans, compose 10-15% of the articular cartilage mass and occur in two forms:
aggregating and non-aggregating. Small, non-aggregated proteoglycans are composed of a core
protein with numerous sulfated glycosaminoglycans (GAGs), mostly chondroitin sulfate and
keratin sulfate, attached laterally. Aggregated proteoglycans form when the core proteins of
multiple non-aggregated proteoglycans bind to a hyaluronic acid by link proteins creating a large
aggrecan. The most important feature of these aggrecans is the high concentration of GAGs.
These GAGs carry negatively charged anions groups with mobile counter ions, like Na+, which
create a large difference in ion concentration between the local tissue and cartilage. The osmotic
imbalance can only be corrected through water entering the tissue because aggrecans cannot
move in the collagen network due to their large size. Once the water is inside the tissue, the
3

negative charge on the GAG groups strongly attracts and binds the water molecules, which make
up 65-80% of the total mass of articular cartilage. This attraction and binding causes cartilage to
swell with water until it is stopped by the tension in collagen network or by an external load.
This compressive turgor allows articular cartilage to evenly distribute loads across the tissue and
resist compressive forces due to the resistance of water leaving the matrix 8–14.
1.3.2

Structure
Articular cartilage’s structure can be divided into four zones: superficial, transitional,

radial, and calcified (Figure 1.1). These zones are organized by the arrangement of the ECM and
chondrocytes within the articular cartilage. The superficial zone is the thinnest layer and
represents 10-20% of the tissue’s volume. It is composed mostly of collagen and chondrocytes
while having the lowest proteoglycan content, but the highest water content. The chondrocytes
are flattened and elongated in this zone, and along with the collagen fibers are aligned parallel to
the articular surface. The alignment of the collagen fibers provides great tensile and shear
strength for the tissue. It also has a thin protein coating of lubricin which lubricates the collagen
surface for smooth gliding. The superficial zone features the highest water permeability
allowing for diffusion of water across the articular surface while acting as a filter for large
macromolecules. Next, the transitional zone comprises 40-60% of the total volume of the tissue.
The collagen fibers are thicker in this region and have random orientations, while the
chondrocytes take on an oval shape as they are embedded in the ECM. The transitional zone has
a lower water content and increased proteoglycan content, which gives resistance to compressive
forces. The third zone is the radial zone which takes up 30-40% of the tissue’s volume and
features the thickest collagen fiber arranged in bundles perpendicular to the surface. The
chondrocyte density is the lowest in this region with chondrocytes taking on a spherical shape
4

that is organized in columns perpendicular to the joint surface. This zone has the highest
proteoglycan content, the lowest water content, and the lowest permeability to water which leads
to the zone having the highest resistance to compressive forces. The last zone is the calcified
zone which consists of collagen fibers from the radial zone that anchor the cartilage to the
subchondral bone. The calcified zone has a distinct physical border, the tidemark, between it and
the radial zone that is created through the calcification of the ECM as it transitions into the
subchondral bone. There is a small volume of chondrocytes in this area which have a
hypertrophic phenotype and an increased ability to synthesized Type X collagen. Type X
collagen acts as a shock absorber and an element of structural integrity as the cartilage transitions
to the subchondral bone 8,10–12.

Figure 1.1

Cartilage Zone Diagram

The cartilage is missing chondrocytes due to decellularization.
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1.4
1.4.1

Focal Lesions
Background
The information on the cartilage structure can be utilized to determine how osteoarthritis

forms in the joint by a focal lesion. Lesions develop in articular cartilage in various ways and
naturally progress into osteoarthritis. An articular cartilage lesion is a term used to encompass
any injury where the articular cartilage of a joint is damaged and is synonymous with the terms
damage and defect. There are two types of lesions that affect articular cartilage: degenerative
lesions and focal lesions. Degenerative lesions are poorly defined defects that are caused by
malalignment, ligament instability, meniscal injuries, or osteoarthritis. A focal lesion is a welldefined defect in the cartilage that is caused by trauma, osteonecrosis, or osteochondritis
dissecans. Osteochondritis dissecans is a joint condition that develops when the subchondral
bone dies from lack of blood flow resulting in the bone and articular cartilage breaking loose
which causes pain and hinders joint movement; it occurs most often in adolescents and children.
The most common causes of osteochondral lesions are trauma from sports injuries or accidents
that are single impact or repeated micro-traumas to the articular cartilage. Over time, lesions
grow in size and severity because the healthy cartilage surrounding the lesion is subjected to new
mechanical forces. These conditions lead to apoptosis and ECM degradation, which causes the
lesion to expand in size and depth. This means even small lesions can develop into osteoarthritis
if left untreated. A study from Hier et al. 15 shows that focal defects have as much of a negative
impact on patient’s quality of life as osteoarthritis does8,15–19.
1.4.2

Evaluation of Osteoarthritis and Focal Lesions
The most common ways osteoarthritis is evaluated in a patient’s joint is radiographs or

arthroscope exploration. General joint osteoarthritis severity is accessed by radiographs using
6

the Kellgren-Lawrence grading. This scale rates a joint from a grade of 0-4 based on joint space
narrowing, osteophytes, sclerosis, and bone deformity. The full Kellgren-Lawrence grading
scale is shown in Table 1.120,21. The severity of a focal lesion is determined by exploratory
surgery or arthroscopy and evaluated using the International Cartilage Repair Society (ICRS)
grading scale (Table 1.2). The ICRS uses lesion depth and subchondral bone penetration to
establish lesion severity 22,23.
Table 1.1

Kellgren-Lawrence Radiographic Grading Scale for Osteoarthritis Criteria

Grade

Characteristics

0

No JSN* or reactive changes

1

Doubtful JSN and possible osteophyte lipping

2

Possible JSN and Definite osteophytes

3

Definite JSN, moderate osteophytes, some sclerosis, and possible bone-end deformity

4

Marked JSN, large osteophytes, severe sclerosis, and definite bone-end deformity

*JSN – joint space narrowing and is <3mm of the joint space or <50% of the other compartment.
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Table 1.2

The International Cartilage Repair Society (ICRS) Grading Scale
ICRS Grade

Focal Lesion Attributes

0 - Normal

No damage

1 – Nearly Normal

Superficial lesions

2 - Abnormal

Lesion extends to less than 50% of the cartilage depth
Lesion extends to over 50% of the cartilage depth but does

3 – Severely Abnormal
not enter the subchondral bone
4 - Severely Abnormal

1.4.3

Full depth lesion that extends into the subchondral bone

Treatment
The current treatments for focal lesions and osteoarthritis include chondroplasty,

microfracture, autologous chondrocyte implantation (ACI), and total joint replacement
depending on how far the lesion or disease has progressed. Chondroplasty and microfracture are
the first treatment choices and are used to treat small articular cartilage lesions. Chondroplasty is
an arthroscopic surgery used to remove loose fragments of cartilage from the joint along with
any debris that may be hindering movement. This treatment option slows a lesion’s growth and
corrects any locking in joint movement caused by loose pieces of cartilage and debris.
Chondroplasty is only used for lesions that do not extend through the full depth of the cartilage.
Microfracture is an arthroscopic surgery done by removing the unstable cartilage of a lesion from
the bone leaving a stable perpendicular edge to the healthy articular cartilage. Then multiple
perforations spaced 3-4 mm apart to avoid breaking the bone plate are created in the subchondral
8

bone of the clean defect. Bone marrow and blood enter the defect forming a clot that promotes
new cartilage formation in the form of fibrocartilage, a type of scar tissue formed from a
combination of fibrous and cartilaginous tissue. This replacement tissue has inferior mechanical
properties when compared to native articular cartilage and it deteriorates over time.
Microfracture is most successful for younger patients (40 or under) with smaller traumatic
lesions less than Ø 2-3 cm, and involves at least six to eight weeks of no weight bearing on the
joint and the use of a continuous passive motion (CPM) machine for six hours per day16,24–26.
ACI is reserved for larger defects that microfracture and chondroplasty cannot treat or as a
treatment option for a failed chondroplasty or microfracture. ACI occurs in three stages with the
first stage involving cartilage being harvested from a lower weight bearing area from the patient.
The harvested cells are then expanded in vitro for four to six weeks. During the third stage of the
procedure, the patient undergoes a second surgery where the lab grown chondrocytes are
implanted into the defect under a collagen or periosteal membrane. ACI has been shown to form
hyaline like tissue in the defect area and provide pain relief and restored joint function in 80-90%
of patients 27,28. The complications associated with ACI are chondrocyte migration from the
treated defect; uneven chondrocyte distribution; hypertrophy of the periosteal; damage to the
donor area; and a six-month recovery period to fully return to normal daily activities. The
surgery criteria are also restrictive requiring the patient to be between 15 to 40 years of age with
a well contained full-thickness femoral chondral lesion around Ø 2-10 cm with an intact bone
bed 16,25,26. If the treatments mentioned above did not slow the progression of osteoarthritis the
final end stage treatment is total joint replacement 29. Total hip arthroplasty (THA) and total knee
arthroplasty (TKA) have shown to have positive outcomes and patient satisfaction. Both
replacements have revision rates of about 6% after 5 years and 12% after ten years 30. Total joint
9

replacement directed toward younger more active patients does have downsides. These patients
will most likely need at least one revision in their life time, and a revision to THA and TKA have
worse outcomes and more complications then the original procedure27.
1.5
1.5.1

Osteochondral Autograft/Allograft Transplantation
Background
The studies discussed in this dissertation will focus on a surgical technique not mentioned

in the previous section called the osteochondral autograft/allograft transplantation (OAT). The
OAT repairs an osteochondral focal lesion through the implantation of an autograft or an
allograft. Autographs are taken from a donor site in the patient’s body and implanted fresh at
defect site. Alternatively, allografts are taken from another individual of the same species and
implanted into the patient and can come from a living or dead donor. The autograft version of
OAT surgery is used for smaller defects (1.0 - 4.0 cm2) due to the limited supply of healthy, low
weight bearing areas of cartilage and subchondral bone available from the patient. The graft is
acquired as a cylindrical osteochondral plug from the donor site. The graft is then impacted into
the site of the defect until it sits flush with the articular surface. This can be accomplished with
either a single graft or multiple grafts, mosaicplasty, depending on the size of the defect. The
allograft version of OAT is used for larger defects (>10 cm2) that autografts cannot treat, and the
surgery is performed in a similar manner. However, fresh allograft is used in the technique
which requires harvesting of the graft within 24 hours of death from the donor. The longer the
graft is stored the lower the chondrocyte viability which in turn lowers the clinical success of the
graft 31,16,32.
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1.5.2

Advantages and Disadvantages
The advantages of OAT when compared to other surgical treatments are a single-stage

procedure that allows for small and large lesions to be corrected; minimal complications and low
rejection rate; and a low immunogenic response even with the use of allografts. One of the most
important factors is OAT covers the focal lesion with functioning cartilage and corrects
subchondral bone defects. The procedure also has a high success rate with a 5-year patient
satisfaction rate around ~87% and 10-year rate at ~78%. When compared to ACI, OAT has
faster recovery time and lower cost associated with the procedure.
The autograft and allograft do have different disadvantages between the two procedures.
Autografts have a limited number of grafts that can be taken from the donor site and the donor
site morbidity associated with collecting grafts. This is compounded with complications from a
mosaicplasty that include: difficulty in coordinating the height and direction of the plugs with the
native cartilage, gaps between plugs due to their shape, and fibrocartilage filling in the gaps
between plugs. When comparing the allograft and the autograft versions of the procedure the
allograft has the advantages of having a large uniform graft, no mosaicplasty complications, and
no donor site morbidity. Consequently, allografts are in low supply, often have a high cost,
increased recovery time, and have the potential of immune rejection and disease transmission.
Also, the timing of the surgery can be difficult to plan because it needs fresh allograft from a
cadaver 33–37.
1.6
1.6.1

Xenografts
Source
To solve the problems with allografts and autografts, these studies will investigate the use

of a third type of graft, an osteochondral xenograft (OCXG), for use in the OAT surgery. A
11

xenograft is similar to an allograft, but it comes from a donor of a different species than the
patient. Xenografts possess the necessary composition and mechanical structure that can be
easily integrated into the native tissue. Currently, the pig is considered the most viable candidate
for potential graft source in xenotransplantation. The pig’s anatomy and physiology are
remarkably similar to humans in size and function, which is key for xenotransplant success. Pigs
have one of the highest articular cartilage thickness to size ratios of the large breed domestic
animals (sheep, goat, horse, canine, and cow) with a range of 0.5-2.0 mm for laboratory bred
mini-pigs and 3.5-4.0 mm for commercial bred pigs, which is comparable to the general human
cartilage thickness of 2-4 mm 13,38–40. The microstructure of porcine cartilage shares the same
distinct four zone organization as human articular cartilage with a leaf like collagen arrangement
in humans and dogs, as opposed to the columnar arrangement seen in rat, rabbit, cow, and
sheep33,38,39,41. The general joint curvature and size are proportional to humans. They have a
wider trochlear groove in the knee compared to other large domestic animals, which matches
closer to human anatomy. The main differences between the pig and human knee anatomy arises
from humans being bipedal and pigs being quadrupedal. This causes the amount of stress
experienced by the hip and knee joints to be different which leads to differences in cartilage
thickness. For example, pigs experience lower amounts of loads in the hip joint causing the
cartilage around the femoral head to be thinner42,43.
Pigs have other advantages then their physiology and anatomy. They have less
economical and ethical issues when compared with other species of usable animals, like
nonhuman primates or companion animals like dogs. Pigs have been bred and raised on farms
for thousands of years for their meat, which leads to a high supply of animals that are available at
a lower cost, a cheaper husbandry cost, and a possible partnership with the food processing
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industry to further reduce cost. When compared to other large animals they give birth at higher
numbers (5-12 offspring per litter) and reach adult human size (~6 months) much quicker
resulting in a quick, sustainable source of grafting material unlike allografts. The risk of
zoonosis is extremely low. This is an advantage over allografts and other non-human primates
where the risk of disease transmission between donor and patient are greater. Finally, there has
been extensive research on the pig’s genome and genetic engineering of the animal. The
emergence of new technologies like ,CHISPR/Cas9, allow for cheaper and faster genetic
manipulation, which could reduce the risk of zoonosis and antigen expression from the pig 43–46.
1.6.2

Decellularization and Antigen Removal
The biggest hurdle with using a xenograft is host rejection of the graft. Host rejection

can happen in three different stages: hyperacute rejection, acute rejection, and chronic rejection.
Hyperacute rejection is an aggressive rejection that happens within hours to minutes of
implantation of the graft caused by pre-established antibodies that react to xenogeneic material.
If the graft is not removed immediately, it will cause organ failure and graft destruction. Acute
graft rejection occurs a week to several months after implantation and is caused either by T-celldependent acute cellular rejection or B-cell-dependent acute humoral rejection with both leading
to graft failure and destruction. Finally, chronic rejection happens months to years after
implantation and is caused by numerous different factors that slowly lead to graft failure and
destruction. The information on chronic rejection of xenogeneic tissue is small because most
grafts fail during the hyperacute and acute stages of transplantation and rarely progress to the
chronic stage. Looking at allograft rejection may provide insight. The major histocompatibility
complex (MHC) expressed on donor cells leads to rejection and there are increasing antibody
titers against other non-MHC antigens found in the grafts47–49.
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To prevent the three forms of rejection, a xenograft needs both decellularization and
antigen removal 47. Decellularization is the process of removing native cells from a tissue to
isolate the extracellular matrix of the tissue via osmotic, chemical, enzymatic, and mechanical
techniques. This ECM is then used a scaffold for new tissue growth. Antigen removal is the
process of removing proteins, polysaccharides, lipids, or nucleic acids that cause immune
rejection of the graft. The difference between decellularization and antigen removal is although
decellularization does remove antigens from the tissue its main goal is isolating the ECM for
scaffold use, and still has the chance of leaving behind antigens.
The most important antigen to remove from a xenograft for human implantation is
galactose-alpha-1,3-galactose (α-Gal). All non-primate and New World monkeys express the αGal epitope on their cell surfaces with glycoproteins and glycolipids. During evolution, humans
lost the ability to create the enzyme α1,3-galactosyltransferase which incorporates the α-Gal
epitope on the cell surface. Humans also produce a xenoreactive antibody, anti-Gal, that is
natural circulating through the body due to gut bacteria expressing α-Gal on mucosal surfaces.
Having anti-Gal antibodies constantly circulating through the body means that any implanted
xenograft containing large amounts of α-Gal antigens is quickly rejected, which is the leading
cause of hyperacute rejection in humans47,50–52.
In work done by Kheir et al.53, the use of freeze/thaw cycles, osmotic shock, detergent,
and nucleases accomplished decellularization in porcine osteochondral plugs with favorable
results of antigen removal. One hypotonic/SDS cycle of decellularization reduced the DNA
content of the cartilage by ~52%, no reduction in collagen content, reduction of ~31% in GAG
content, and loss of compressive stiffness during the indentation by over 50%. Increasing the
number of cycles to 6 and 9 further reduced the DNA and GAG to over 90% but did not reduce
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the compressive stiffness more than a single cycle. In another study by Elder BD et al. 54,
decellularization of cartilage was accomplished using 1% or 2% sodium dodecyl sulfate (SDS),
2% Tributyl Phosphate (TnBP), 2% Triton X-100, or Hypotonic/ Hypertonic solutions , with all
solutions including a treatment of 0.5 mg/ml DNase Type I, 50 μg/ml RNase, 0.02% EDTA, and
1% Penicillin/Streptomycin/Fungizone (P/S/F) in PBS. Triton, TnBP, and the
Hypotonic/Hypertonic solutions either did not provide adequate decellularization or severely
reduced the mechanical properties of the cartilage constructs. Both 1% and 2% concentrations of
SDS used in short time frames had good balance of decellularization while maintaining tissue
mechanics and GAG retention. The study concluded that a 2% SDS treatment showed the most
promise for future research in decellularization54. Both studies showed promise in the
decellularization and DNA removal from cartilage, but it should be noted that increased cellular
and DNA removal caused an increased reduction in GAG and mechanical properties. One way
to correct the loss of mechanical strength created by decellularization can be done by
crosslinking the decellularized graft.
1.6.3

Crosslinking
Crosslinking is the binding of one polymer chain to another, an example is shown in

Figure 1.2, and is commonly done by linking proteins together in biology. Chemical or
photooxidation collagen crosslinking can restore mechanical properties to decellularized tissue
and has the added benefit of lowering the immune response, masking antigens, and lowering the
degradation rate of tissue.
This research focuses on the crosslinking of type II collagen in the ECM of cartilage to
correct the loss of mechanical strength of grafts from antigen removal. The chemical
crosslinking agents are advantageous over other crosslinking methods because of their ease of
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use and ability to be scaled for large batch graft production. One of the most common
crosslinking agents is glutaraldehyde, which has been used in bioprosthetic heart valves for many
years. Studies have also shown that crosslinked bovine meniscal fibrocartilage survived for a
year in good condition when used to resurface a defect created in the canine patella55.
Consequently, glutaraldehyde can inhibit recellularization and ECM turnover with high degrees
of crosslinking. Residual glutaraldehyde from the graft can leach into the tissue causing fixation
and cell death if constructs are not correctly washed47,55. New research has begun to investigate
less cytotoxic alternatives to glutaraldehyde with the use of naturally occurring crosslinkers.
Two natural crosslinkers that are being utilized are epigallocatechin gallate (EGCG) a
polyphenol from green tea and genipin which comes from the fruit of Gardenia jasminoides.
EGCG has strong antioxidative properties along with being antiangiogenic and antitumorigenic,
and in a study comparing the crosslinking of dentin EGCG stabilized collagen more effectively
than glutaraldehyde and genipin56,57. A study comparing genipin and glutaraldehyde
crosslinking of porcine matrices implanted in sheep it was noted that genipin had no cytotoxicity
and depressed the host inflammatory response when compared to glutaraldehyde58. Genipin also
has the ability to support adipose derived mesenchymal stem cells and the ECM created by the
cells in a crosslinked cartilage derived matrix with a 50% crosslinking degree 59. In a recent
study by Pinheiro A. et al. 60, genipin, proanthocyanidin, and EGCG have shown to be just as
effective as glutaraldehyde in their ability to improve the mechanical properties and enzymatic
resistance of decellularized cartilage.
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Figure 1.2

Basic Crosslinking Diagram

Black lines represent different polymers and red lines represent the bonds made by the
crosslinker.
1.7

Dissertation Overview
The ultimate goal of this research is to help develop a therapy that will slow or stop the

progression of focal lesions into osteoarthritis. The main therapy proposed in this body of
research is the creation of an osteochondral xenograft (OCXG).
1.7.1

Aim 1
The first aim was to explore the effectiveness of different decellularization and antigen

removal techniques on porcine OCXGs. At the time of the first study there were few published
studies that described the effectiveness of decellularization and antigen removal for articular.
Therefore, this study compared the mechanical, biochemical, and histology of three different
decellularization techniques in vitro and in vivo using a rabbit model. The best technique was
then chosen for the future work in these studies.
1.7.2

Aim 2
The second aim was to investigate the differences between genipin and EGCG in their

ability to crosslink the decellularized OCXG. This was done using an in vivo rabbit model and
evaluating the gross appearance, bone integration, and cartilage integration in the joint.
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1.7.3

Aim 3
The third aim was to investigate the efficacy of a genipin-crosslinked OCXG in a long-

term large goat model. It included degree of crosslinking as a variable.
1.7.4

Aim 4
The fourth aim was to investigate the effectiveness of genipin and punicalagin to mitigate

cartilage damage when directly injected in the joint. This aim was not directly related to the
development of the OCXG, but leveraged the knowledge gathered on chondroprotective
substances during the development of OCXG. Both punicalagin and genipin had shown different
mechanics of stabilizing collagen and increasing resistance to collagenase. The pilot study
evaluated the efficacy of injecting genipin and punicalagin in slowing chemically induced OA in
a rat model.
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CHAPTER II
A COMPARISON OF DECELLULARIZATION METHODS
2.1

Introduction
The aim of the study was to investigate the effectiveness of three different

decellularization and antigen removal protocols. At the time of this study there were few
publications discussing the decellularization and antigen removal of articular cartilage. The
main group of publications were done by Elder et al. 54 for just articular cartilage and Kheir et
al.53 for full cartilage and bone constructs. Kheir’s decellularization protocol was chosen for the
study, while we adapted a protocol for myocardium decellularization by Wang et al.61 and a bone
decellularization protocol by Xie et al. 62. These varied selections of protocols allowed for
diversity in the decellularization techniques being evaluated.
We selected the rabbit for our small animal model for a variety of reasons. First, the
rabbit knee is similar in gross appearance to the human knee and has the joint size for a Ø 5.0
mm osteochondral defect. Second, our research group has experience with handling, preforming
surgery, and caring for rabbits in our past work. Finally, with the low cost, low care price, and
being able to cage them compactly means our pilot study could have a higher number of animals
for the budget. A potential consequence of utilizing a rabbit model is their endogenous healing
potential which allows them to repair cartilage damage. This was taken into consideration when
translating our OCXG into a larger animal model41,63–65. Our rabbit model design was supported
with other similar successful published studies. Frenkel and Kubiak had a more aggressive
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rabbit model using allograft and autograft to correct two osteochondral defects that were Ø 3 mm
by 5 mm defects 4 mm apart bilaterally with success66. Another, study by Yoshioka et al. 67 used
a rabbit model to test allogeneic cartilage aggerates in osteochondral defects sized at Ø 5.0 mm
by 4 mm with no problems.
2.2
2.2.1
2.2.1.1

Methods
Scaffold Fabrication
Tissue Samples
Thirty-nine osteochondral plugs sized at Ø 5.0 mm by 8 mm (range 7- 9 mm) were

harvested from adult porcine stifle joints obtained from a local meat processor using a trephine
attached to a power drill. The trephine was placed perpendicular to the articular surface so plugs
would have a flat articular surface. After extraction, fresh plugs (Figure 2.1) were split into 4
groups of 3 experimental groups with 11 plugs in each group and 1 control group with 6 plugs.
Extra plugs were added to groups to allow for the surgeon to select for optimal grafts during
implantation. Groups were then placed in separate 50 ml tubes and washed in PBS, 1mM PMSF
and 1% antibiotic-antimycotic at room temperature for 3 hrs under orbital shaking and then
frozen at -20 °C in fresh solution. Plugs were thawed at room temperature at the start of
decellularization for experimental groups or testing for controls.
2.2.1.2

Decellularization Protocol 1
This decellularization protocol was based on the method described by Kheir et al. 53.

First, grafts were exposed to two rounds of dry freeze-thaw. Grafts were frozen together in a
50ml tube until crystal formation at -20 °C and then thawed at room temperature for 4 hrs on the
lab bench for each round. The grafts were submerged in a hypotonic buffer (10 mM tris-HCl,
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pH 8.0) and then exposed to two more rounds of freeze-thaw using this buffer. After the final
thaw, the solution was refreshed, and grafts were incubated for 24 hrs at 45ºC. Next, grafts were
incubated at 45ºC under agitation in detergent (0.1% [w/v] sodium dodecyl sulfate (SDS) in
hypotonic buffer) with aprotinin (10 KIU.mL-1) and 0.1% (w/v) ethylenediamine tetraacetic acid
(EDTA) for 24 hrs. Once complete, two washes in PBS with aprotinin were done for 30 min and
then one wash for 24 hrs at 45°C all under agitation. Grafts were then incubated for 3 hrs at
37ºC in nuclease solution (50 mM Tris solution, pH 7.5, with 10 mM magnesium chloride and
50 lg mL-1 of bovine serum albumin) with DNase (50 U mL-1) and RNase (1 U mL-1). Once
incubation was complete, grafts were washed in PBS with protease inhibitors. Sterilization was
done by a room temperature incubation of the grafts in a solution of 0.1% (v/v) peracetic acid in
PBS for 3 hrs. This was followed by two washes in Sterile PBS for 30 min, and a final single
wash for 24 hrs at 45°C. Finally, grafts were split into 2 groups with the 6 best grafts being
selected for implantation and the 5 remaining grafts being used for mechanical and biochemical
testing.
2.2.1.3

Decellularization Protocol 2
This decellularization protocol was adapted from a myocardium decellularization

protocol developed by Wang et al. 61. Osteochondral grafts were decellularized in a detergent
solution (0.25% SDS, 1mM PMSF, 0.01%, 20 ug/ml RNase, and 0.2 mg/ml DNase) under
agitation for 11 days at room temperature. During the 11 days, solutions were changed every 3
days along with samples receiving a 10 min ultrasonic treatment (50Hz). After the 11 days,
grafts were washed in PBS twice for 1 hr. The grafts were then sterilized in two washes of 70%
EtOH for 2 hrs each and then washed with sterile PBS. Grafts were split into 2 groups with the 6
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best grafts being selected for implantation and the 5 remaining grafts being used for mechanical
and biochemical testing.
2.2.1.4

Decellularization Protocol 3
This decellularization protocol was adapted from Xie et al 62 and is a partial

demineralization and deproteinization designed for bone-derived scaffold material for critical
bone defects. First, grafts were immersed in 10% hydrogen peroxide for 24 hrs at 38°C, which
was followed by the grafts being partially demineralized with 0.6N hydrochloric acid for 3-4 hrs
at room temperature. The grafts were then incubated at room temperature for 1 hr in
chloroform/methanol (1:1) and then in 0.25% trypsin for 12 hrs at 4°C. The last step involved an
incubation of the grafts in 0.5% SDS for 6 hrs at room temperature. Afterwards, the grafts were
stepped through multiple extensive washes with distilled water ending in lyophilization. Grafts
were split into 2 groups with the 6 best grafts being selected for implantation and the 5 remaining
grafts being used for mechanical and biochemical testing. The grafts selected for implantation
experimentation were further sterilized by gas sterilization.
2.2.2

Rabbit Surgery
All animal experiments were approved by MSU’s IACUC (Protocol # IACUC-13-027)

board. This pilot study involved 6 healthy male rabbits weighing approximately 4 kg. Rabbits
were pre-medicated intramuscularly with ketamine (10 mg/kg body weight), Midazolam (0.1
mg/kg body weight), and buprenorphine (0.015 mg/kg body weight). An intravenous catheter
was placed in the marginal ear vein before anesthesia was induced and a lactated Ringer’s
solution (10 ml/kg/hr) was administered. Rabbits were anesthetized by mask and maintained
with endotracheal intubation using 1% isoflurane and oxygen. Both hind legs were clipped and
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prepared for aseptic surgery. During surgery, the rabbits’ vital signs were continuously
monitored (e.x.: blood oxygen saturation, blood pressure, EKG, temperature). The stifle joint
cavity was accessed through a parapatellar incision and lateral dislocation of the patella. A fullthickness chondral defect (5 mm dia. x 6 mm depth) was created in the central part of the
trochlear groove by slow speed drilling under saline irrigation. The defect was immediately
filled with one of the decellularized OCXGs cut to length of the defect size allowing the graft to
sit flush with the host cartilage to create a smooth surface and was secured by anchored
interference fit. The incision was then closed in layers and rabbits were monitored until they
fully recovered. The OCXGs were selected so no rabbit received the same type of graft in both
knees and each method was represented 4 times. Three rabbits containing 2 constructs from each
method were euthanized at 2 weeks and then at 8 weeks after surgery to assess the inflammatory
response and cellular infiltration of the xenograft. Following euthanasia, the joints were
radiographed mediolateral to assess bone healing in the joint. The joints were then opened, and
the gross anatomy was evaluated. Lastly, joints were removed and fixed in 10% buffered
formalin in preparation for histology.
2.2.3

Histology
Non-implanted samples were fixed in 10% buffered formalin and decalcified in formic

acid. Sections were then embedded in paraffin and stained with Hematoxylin & Eosin (H&E),
Toluidine Blue, and Picrosirius Red. ImageJ software was used in the analysis of H&E histology
to determine the percentage of cells that still retained their nuclei after decellularization.
Toludine Blue and Picrosirius Red staining were qualitatively analyzed to observe GAG and
collagen washout. Implanted scaffolds were fixed in 10% buffered formalin, decalcified in
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formic acid, and sections were then embedded in paraffin and stained with H&E. H&E sections
were qualitatively observed to determine graft integration.
2.2.4

Biomechanical Testing
Biomechanical testing of the non-implanted cartilage was done with a Mach-1

Mechanical Testing System equipped with a 100 N load cell. The testing required the separation
of the cartilage from the bone followed by trimming of the cartilage, both done with a scalpel.
The cartilage pieces (n=5 per group) were trimmed to ~ Ø 4.7 mm and a uniform thickness of 1
mm. Before compression testing the sample, the thickness was found by placing each sample
between two flat plates and finding the contact force at 0.1 N. Samples were placed inside a Ø
4.7 mm steel chamber with impermeable sides and bottom and then compressed by the Mach-1
using a Ø 4.3 mm free-draining porous indenter. The load was ramped to 0.45 N at 0.05 mms-1
and allowed to relax for 10 min. Compression was then ramped to an engineering strain of 10%
strain at 0.05 mms-1 and load was recorded at 10 Hz until the relaxation was less than 0.05 Nmm1

. The aggregate modulus (Ha) and permeability (k) were found by least squares curve fitting of

the stress relaxation data to the biphasic model68.
The unconfined compression testing of the nonimplanted bone (n=5) was done with an
Instron 1011 Universal Testing Machine running series IX software. After separation from the
cartilage, the ends of the bone cylinders were trimmed with a hobby saw to create faces that were
perpendicular to the long axis and the height of the sample was measured with digital calipers.
The bone was then loaded to failure between smooth impermeable plates at a constant rate of
0.01 mms-1. Young’s modulus was determined by using the slope of the best fit line though the
linear region of the stress-strain curve.
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2.2.5

Biochemistry
The biochemistry used five samples from the control group and each decellularization

protocol that were never implanted but reserved for later testing. Each sample had its wet weight
determined and then was digested in a solution of papain in a PBE-10 mM cysteine buffer (2.5
mg papain enzyme to 20 mL PBE-cysteine, pH 6.5) for 24 hrs at 60°C. The papain digested
samples were then centrifuged at 10,000 G for 5 min and the supernatant was collected for use in
DNA and GAG quantification.
DNA was quantified first using the Hoechst DNA assay. DNA standards were created
using calf thymus DNA (1 mg/mL) that was serial diluted in the papain and PBE-cysteine
solution to create DNA standards of 2000, 1000, 500, 250, 125, and 0 ng. Then, 50uL of the
experimental sample and each standard were added to a 2 mL solution of 1X TNE buffer
containing 0.2 ug/mL Hoechst dye (2 μl stock Hoescht per 100 ml TNE), agitated, and
immediately had their fluorescence measured on a GloMax Jr (Promega) using the UV Kit
(Excitation wavelength: 365 nm, Emission Wavelengths: 410-450 nm). The DNA standards
were plotted to generate a standard curve. The experimental results were then compared to the
DNA standard curve to see if the experimental results fell outside of the curves’ upper or lower
bound. When the reading was under the curve the volume of the papain solution was increased
or papain volume was decreased when the reading was above the standard curve. DNA content
was then calculated using the standard curve and each sample was normalized using the wet
weight. A two-sample t-test (α=0.05) was used to compare experimental groups individually to
the control group.
The remaining papain digested samples were used to calculate GAG by quantification
using the Blyscan Sulfated Glycosaminoglycan Assay Kit (Biocolor), which is based on the
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binding of 1,9-dimethyl-methylene blue (DMB) dye to sulfated polysaccharide component of
proteoglycans or the protein free sulfated GAG chains. Standards were created using bovine
tracheal chondroitin 4-sulfate by suspending 0, 1, 2, 3, 4, and 5 µg in 100 µL of PBE buffer
added to separate microcentrifuge tubes. 50uL of each sample was added to a separate
microcentrifuge tube and brought to 100 µL using PBE buffer. Next, all tubes had 1 mL of
Byscan dye reagent added and were mixed by inverting the contents and having the tube gently
agitated using the mechanical shakers for 30 min. All tubes were then centrifuged at 12,000
RPM for 10 min to form small pellets at the bottom of the tubes. Tubes were then inverted and
drained carefully to prevent any loss of the pellet while removing unbound dye. Each tube then
had 0.5 mL of dissociation reagent added and vortexed. They were then incubated at room
temperature for 10 min to allow for full dye unbinding. Tubes were centrifuged at 12000 RPM
for 5 min to reduce foam. Individual samples had 200 µL of solution transferred to a well of a
96-well plate and absorbance was measured at 656 nm on the μQuant Microplate
Spectrophotometer (Biotek, Winooski, VT). The OD values of GAG standards were then plotted
to form a standard curve. Experimental OD values were compared to the curve generated by the
standards to determine GAG concentrations. Final values were normalized to the wet weight of
the cartilage. If the experimental values were either above or below the standard curve the
concentration was reduced or increased, respectively, until the sample read within the curves
range. A two-sample t-test (α=0.05) was used to compare experimental groups individually to
the control group.
The separated bone (n=5) cylinders were tested for their calcium content using the
Stanbio Calcium (CPC) LiquiColor kit. Each bone cylinder was put into its own centrifuge tube,
lyophilized, and weighed to obtain their dry weights. Samples then had 0.6 M Hydrochloric acid
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(HCL) added to each centrifuge tube at 500 uL per 1 mg and left under room temperature
agitation until the bone was completely dissolved. Samples were analyzed using the Stanbio
Calcium (CPC) LiquiColor kit. The reagent blanks, calcium standards (1, 2 , 4 , 6, 8, and 10
mg/dL), and samples had their absorbance value read using the GloMax Jr at 550 nm with the
blank value subtracted from the final absorbance values for the control and experimental
samples. If samples values were over 15 mg/dL samples had to be diluted till they fit within the
linear region of the standard curve. Samples were then normalized by their dry weight. A
Dunnett’s post-hoc test and one-way ANOVA were used to compare experimental groups
individually to the control group at a significance of α=0.05.
2.3
2.3.1

Results
In Vitro Testing: Histology, Biomechanical Testing, and Biochemistry
The biochemical (Figure 2.2, Table 2.1), biomechanical (Figure 2.3, Table 2.1), and

histology (Figure 2.4, Figure 2.5, Table 2.1) results were able to quickly differentiate between
the different decellularization protocols. Grafts from decellularization protocol 1 (Figure 2.1)
exceled at removing DNA and GAG at ~85% and ~95%, respectively, and did not remove any
calcium from the bone. Despite having the best antigen removal there was an increase in the loss
of mechanical properties of the tissue with the aggregate modulus of the cartilage being reduce
by ~85% and the Young’s modulus of the bone being reduced by ~53% when compared to the
control tissue. The histology confirmed the biochemical results with cells showing 84.43%
removal of the material from the lacuna of the cartilage. Toluidine Blue staining compared to
the controls and the other protocols had no purple staining at the superficial zone, light staining
in middle and deep zones, and only deep purple staining close to the tide mark and confirms that
the tissue did lose close to ~95% of its GAG content. The Picrosirius Red staining had near
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complete washout of all red coloring when compared to the controls and other protocols, and
when paired with the reduction of the aggregate modulus suggests that the tissue had a strong
reduction of the collagen matrix.
Grafts from decellularization Protocol 2 (Figure 2.1) exceled at the having the best
retained mechanics of all the protocols. Protocol 2’s cartilage aggregate compared to the control
was reduced by ~60% placing it second among the 3 protocols, but it made up this shortcoming
by having no reduction in the bone’s Young’s Modulus when compared to the control. This
protocol had the least GAG reduction at ~45% and no reduction in bone calcium. Where this
protocol performed poorly was only reducing DNA content by ~44%, which matched closely to
the histology of 48.42% nuclei removed from the cells. The Toluidine Blue staining matched the
biomechanical results showing GAG loss in the superficial and middle zones where there was a
medium purple color compared to the dark purple of the controls. The Picrosirius Red staining
showed a slight washout of collagen content in the deep zone when compared to the control and
protocol 3 which had column like red staining in the deep zone.
The grafts from decellularization protocol 3 (Figure 2.1) excelled at reduction of calcium
in the bone section of the plug and reduced it by ~73% when compared to the control. This did
have a negative effect on the mechanics of the bone and reduced the Young’s modulus the most
at ~63%. These negative effects did not show in the cartilage mechanics where this protocol had
the smallest reduction of the aggregate modulus at ~45%. The Picrosirius Red staining had some
color washout in the middle zone, but the tissue retained the columnar/band collagen staining as
seen in the control. Combing this histology with the aggregate modulus data shows that this
protocol had the smallest destructive effect on collagen content. Protocol 3 reduced GAG down
to ~55% of the control’s GAG content with Toluidine Blue confirming the trend with the
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superficial and middle zone having a lighter purple color than the control and protocol 2, which
both had higher GAG contents. Lastly, this protocol removed ~72% of DNA with respect to the
controls, but the histology showed conflicting data with cells only having ~1% of their nuclei
removed.

Fresh Tissue

Control

Decellularization
Protocol 1

Decellularization
Protocol 2

Decellularization
Protocol 3

Figure 2.1

Images of the Grafts at Each Step in the Decellularization Process
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Figure 2.2

Graphs of Biochemical Testing Results for OCXGs
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Figure 2.2 (continued)
*Designates a statistical difference with respect to the control (α=0.05).
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Figure 2.3

Graphs of Biomechanical Testing Results for OCXGs

*Designates a statistical difference with respect to the control (α=0.05).
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Figure 2.4

Hematoxylin & Eosin Histology of OCXGs
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Figure 2.5

Toluidine Blue and Picrosirius Red Histology of OXCGs

34

Table 2.1

Histology, Biochemical, and Biomechanical Data Summary of OCXGs
Control

Decellularization
Protocol
1

Decellularization
Protocol
2

Percentage of
nuclei removed
N/A
84.43%
48.42%
from cells
DNA
normalized to
1.5076±
0.1982± 0.0364* 0.8498± 0.2017*
wet weight
0.3310
(µg/mg)
GAG
normalized to
99.018± 28.26
4.678± 2.87*
54.736± 9.96*
wet weight
(µg/mg)
Calcium
normalized to
115.93± 21.34
137.0± 11.45
93.21± 33.31
dry weight
(µg/mg)
Aggregate
Modulus of
0.1397±0.04 0.0213± 0.0026* 0.0552±0.0035*
Cartilage
(MPa)
Young’s
Modulus of
167.88± 82.58
79.32± 39.69*
167.93± 44.56
Bone (MPa)
*Designates a statistical difference with respect to the control (α=0.05).
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Decellularization
Protocol
3
~1%

0.4186± 0.2067*

44.765± 16.81*

30.79± 23.62*

0.075±0.0075*

62.70± 49.25*

2.3.2

In Vivo Testing: Rabbit Model
Starting with the evaluation at the two-week end point (Figure 2.6), decellularization

protocol 2 performed the best out of the 3 protocols. Protocol 2 was implanted in rabbit 3 (left)
and rabbit 1 (right) which both had the smallest immune reaction. The radiographs showed light
integration of the graft into the bone. The cartilage interface in rabbit 3 was still intact and had
fibrocartilage growing over it. The graft for rabbit 1’s cartilage interface was intact but only had
a negligible growth of fibrocartilage over it. Protocol 3 was planted in rabbit 2 (left) and rabbit 3
(right) and underperformed versus protocol 2. The graft in rabbit 3 had a minimal immune
response, the best starting bone integration out of the three grafts, but the cartilage interface was
missing with no overgrowth of fibrocartilage. The graft in rabbit 2 differed by having a
moderate immune response which was consistent with seroma. This immune response disrupted
the grafts integration in the bone and cartilage interface. Protocol 1 was implanted in rabbit 1
(left) and rabbit 2 (right) and performed poorly compared to Protocol 2 & 3. Rabbit 1 had a light
immune response, light bone integration, and the cartilage had fibrocartilage growth over the top
with the loss of most of the graft’s cartilage. Rabbit 2’s graft had a moderate immune response
and contained an abscess. This led to having little integration with the bone and no cartilage in
growth with areas of the graft’s cartilage missing. The immune responses of Rabbits 1 and 3
were very slight, but rabbit 2 had a moderate immune response with both grafts. With this being
a pilot study and only having a small number of rabbits, it is not known if this is indicative of the
grafts or one animal having a hypersensitive immune response.
At the 8-week end point (Figure 2.7), each decellularization protocol excelled in different
areas with all having a similar low immune response. Protocol 1 had the best integration with
the bone when compared to the other protocols, but most of the cartilage interface of the graft
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was gone with no overgrowth by the native tissue. Protocol 2 exceled at the integration of the
cartilage interface of the graft. The graft’s cartilage remained intact and had ingrowth of
fibrocartilage over the graft. The graft had the least integration into the native bone. Protocol 3
was the mid performer in bone integration. The histology showed that the graft break
down/reabsorption was the quickest of three protocols, with removal of the cartilage and bone
parts of the graft, and like Protocol 2 there was ingrowth of fibrocartilage over the graft.

37

2 Week End Point
Protocol & ID

Radiographs

Gross Anatomy

H&E

H&E

Decellularization
Protocol 1
#1 Left

Decellularization
Protocol 1
#2 Right

Decellularization
Protocol 2
#3 Left

Decellularization
Protocol 2
#1 Right

Decellularization
Protocol 3
#2 Left

Decellularization
Protocol 3
#3 Right

Figure 2.6

Collage of Mediolateral Radiographs, Gross Anatomy, and H&E Staining of
OCXGs at the Two-Week End Point.

Yellow arrows on radiographs point to graft locations.
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8 Week End Point
Protocol & ID

Radiographs

Gross Anatomy

H&E

H&E

Decellularization
Protocol 1
#4 Left

Decellularization
Protocol 1
#5 Right

Decellularization
Protocol 2
#6 Left

Decellularization
Protocol 2
#4 Right

Decellularization
Protocol 3
#5 Left

Decellularization
Protocol 3
#6 Right

Figure 2.7

Collage of Mediolateral Radiographs, Gross Anatomy, and H&E Staining of
OCXGs at the Eight-Week End Point

Yellow arrows on radiographs point to graft locations.
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2.4

Discussion & Conclusion
The overarching goal of this research was to create an alternative to osteochondral

allografts and autografts that are used in OAT surgery by developing a usable xenograft. The
first step in this process was effectively decellularizing the xenograft. This pilot study
investigated the possibilities of antigen removal and decellularization of the osteochondral
xenografts. At the time of the study, there was a large gap of knowledge in the literature of
cartilage decellularization, so we took the approach of adapting different decellularization
protocols to investigate their effectiveness in cartilage decellularization. As a result, we adapted
three different decellularization protocols: protocol 1 was a freeze/thaw and osmotic shock with
SDS designed for cartilage and bone53; protocol 2 was a detergent decellularization using SDS
that was adapted from myocardium use61; and protocol 3 was a partial demineralization and
deproteinization designed for bone-derived scaffold62. Our optimal decellularization and antigen
removal techniques will aim for the rules set by Crapo et al. 69 with having less than 50 ng of
DNA per mg of ECM and having no visible nuclear material left in the tissue after H&E staining.
Next, the ECM of the graft needs to maintain the same collagen and GAG content when
compared to the original tissue, and the graft needs to maintain the same mechanical properties
as the original osteochondral plug. Lastly the grafts should have minimal to no immune response
when implanted in vivo.
In this early study the main goal in antigen removal was based on the amount of DNA
removal, nuclei removal, and the immune response with in vivo testing. Protocol 1 performed
the best in antigen removal by removing the most DNA and nuclei at around ~85% for both.
Protocol 2 landed in the middle of the road with at least a ~45% reduction of DNA and nuclei
removal, while this is not ideal the protocol has a lot of room for future modifications. The worst
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preforming protocol was protocol 3 which was able to remove ~75% of the DNA, but it was not
able to remove the cellular debris and only 1% of the nuclei in the cells. This leaves two options:
the DNA assay was incorrect or that the protocol does not remove the debris left from the nuclei,
both options are poor and can lead to an increased risk of graft rejection. All protocols did not
meet the standards of <50 ng per mg of dry tissue and full removal of cell nuclei in the tissue.
The performance of implantation in the rabbits was generally the same for all protocols showing
only a small immune response except in rabbit 2 where there was moderate immune response
with both grafts from protocol 1 and 3. The trend did not repeat in rabbit 5, which shared the
similar graft distribution. This supports the conclusion that rabbit 2 was an outlier in the study
and had stronger immune response than normal.
The goals of the decellularization metrics were based on the levels of GAG, collagen, and
calcium content remaining the same as the control tissue. The aim is to minimize the reduction
of collagen and GAG in the cartilage’s ECM and minimize the loss of calcium in the bone
interface. Quantitatively all protocols reduced the GAG content by a significant amount when
compared to the control. Protocols 2 and 3 reduced GAG content around the same amount,
~55% to ~45% respectively, and protocol 1 performed the worse reducing GAG to ~3%. The
qualitative examination of the toluidine blue staining for GAG agreed with the qualitative results
with higher intensity staining with the purple color intensity reducing, going from the deep zone
to the surface. Collagen content was only assessed using picrosirius red but showed similar
trends to the GAG reduction. Protocol 1 performed the worst, removing most of the collagen
content from the graft, while protocol 2 and 3 removed similar amounts around 50% with 3
removing a little more than 2. The reduction in red collagen staining followed a different pattern
than GAG with loss of staining starting at the deep zone and staining becoming more intense as
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it reached the surface layer. Calcium reduction was only seen in protocol 3 where it was reduced
~73% and qualitatively the bone was bleached whiter and noticeably softer to the touch than the
other protocols and the control.
The target for the mechanical properties of the decellularized grafts was to have them
match the control groups aggregate modulus for the cartilage and the Young’s modulus for the
bone in compression. All decellularization protocols did not meet the standard for the aggregate
modulus. They all reduced the aggregate modulus with protocol 1 reducing it the most at a
~85% reduction to the control, protocol 2 reduced it by ~60%, and protocol 3 performed the best
with only reducing it by ~45%. The only protocol that met the standard for the Young’s
modulus the bone was protocol 2 which had no significant reduction of the modulus. Protocol 1
reduced the Young’s modulus by ~53%, while protocol 3 reduced the Young’s modulus by
~63%. The loss in the mechanical strength in the tissues aligns with the reduction of GAG,
collagen, and calcium in the grafts. Protocol 2 had a superior mechanical performance over
protocol 1 & 3 by meeting at least one of the two standards set.
The goals for the in vivo testing were for the grafts to not have a strong immune response
from implantation; maintain the bone and cartilage graft integrity; and have the graft start
integration with the bone and cartilage of the patient. Decellularization protocol 1 lost most of
the grafts’ cartilage in 3 of 4 rabbits with minimal to no native fibrocartilage growth over the
graft. The loss of the cartilage interface is most likely due to the reduction of collagen in the
ECM that was observed only in this protocol. Protocol 1 had the best integration with the bone
at 8 weeks and maintained the bone section of the graft in most implantations. There was one
moderate immune response in rabbit 2 creating an abscess, while the 3 remaining implants only
caused a minor immune response. Decellularization protocol 2 maintained the cartilage and
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bone interface in all implanted grafts. All grafts had fibrocartilage growing over the cartilage
interface with only one having a small growth at the two-week end point. This protocol had a
light integration into the bone but was the least integrated when compared to the other grafts.
Finally, protocol 2 had a minimal immune response in all implantations. Protocol 3 was able to
maintain the cartilage interface which had some fibro cartilage overgrowth. The bone portion
appeared to integrate well on the radiographs, but from examining histology the demineralization
of the bone caused it to be reabsorbed too quickly before the native bone could properly replace
it around the eight-week end point. Like protocol 1 there was a moderate immune response in
rabbit 2 with a seroma, but the remaining implants only cause minor immune responses.
Overall, no decellularization protocol was able to perfectly meet the standards that were
set. They did not remove enough DNA, while removing to much of the ECM in the process.
Protocol 2 performed the best out of the three decellularization protocols. It was able to meet
one of the standards for maintaining the mechanical strength and the calcium content of the bone
interface. It also did not have any large immune response during implantation and was able to
maintain both portions of the graft while starting integration into the native tissue. The main
disadvantage in protocol 3 was the reduction of the calcium and mechanical strength of the bone
interface. Due to the nature of the protocol being a demineralization of bone it is highly unlikely
to change this problem without major alterations to the protocol. The main flaw with protocol 1
was the reduction of the cartilage ECM and aggregate modulus, which outweighed the superior
DNA removal aspects of the protocol. This protocol could be altered to reduce the destruction of
the ECM, but it would take many iterations to refine this protocol because the protocol has many
different steps that could be altered. The more time efficient strategy would be to alter protocol
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2 to be more aggressive at DNA removal because it has fewer steps to achieve decellularization
making the optimization process faster.
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CHAPTER III
A COMPARSION OF CROSSLINKERS
3.1

Introduction
The results from the last study helped establish a reliable decellularization method for

this study. This method was further explored and optimized in work done by other members of
our lab group 70. Utilizing the new method of decellularization, this study focused on how the
two natural crosslinking agents, genipin and EGCG, performed against each other in stabilizing a
focal defect in a rabbit model. The model was similar to the last study, but it did have a few
changes in OCXG size and experimental population size. The diameter of the OCXGs were
reduced from Ø 5 mm to Ø 3.5 mm because the lager diameter grafts size did not allow the graft
to sit flush in the joint surface due to the curve in the patellofemoral groove. The natural
progression of an empty osteochondral defect was already well known, and this study wanted to
focus on exploring the differences between the uncrosslinked and crosslinked OCXGs. To
achieve this, group numbers were changed so each experimental group had 5 rabbits, while the
control group had 3 rabbits. In conclusion, this study builds on the previous OCXG by
investigating which crosslinking option would be the most viable.
3.2
3.2.1

Methods
Graft Preparation
Two stifle joints of a retired sow were obtained from a local meat processor and frozen at

-20℃. The joints were then thawed, and 48 osteochondral plugs were harvested from the
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trochlea grooves using the Smith & Nephew Ø 3.5 mm Mosaicplasty DP Harvesting System at a
length of approximately 8 mm (range 6-10 mm). Following the harvest, 8 plugs were frozen at 20℃ for biochemistry and 3 plugs were immediately placed in 10% buffered formalin for
histology. The remaining plugs were grouped together for decellularization. All
decellularization steps were done under orbital shaking at 37℃ unless otherwise stated. Plugs
were placed in a solution of PBS, 1 mM PMSF and 1% antibiotic-antimycotic at room
temperature for 3 hrs. This was followed by 4 hrs in a 3% hydrogen peroxide solution with a
solution change every hour. Plugs were then placed for 1 hr in chloroform:methanol (1:1) and
then washed for 30 min in methanol followed by washes in distilled water. Finally, plugs were
incubated for 48 hrs in 10 mM Tris-HCl (pH 7.6), 5 mM MgCl2, 0.5 mM CaCl2, 2% SDS, 0.5
mg/ml DNase I, 0.05 mg/ml RNase, 1 mM PMSF, 1% antibiotic-antimycotic mixture with a
solution change after 24 hrs, which was followed by 3 washes in distilled water for 30 min each.
After decellularization, 3 control plugs were placed in 10% buffed formalin, decalcified, and
embedded in paraffin for histology and 8 plugs were frozen at -20℃ for biochemistry. Six of the
controls were then stored at 4℃ in PBS, 1mM PMSF, and 1% antibiotic-antimycotic for
transplantation. The remaining 20 plugs were split into two groups and crosslinked with EGCG
(n=10) or genipin (n=10). Crosslinking was accomplished by placing the plugs for 48 hrs in a
solution of distilled water and 1% wt/vol of EGCG or 0.05% genipin, 40 mL of solution per 10
plugs, under gentle orbital shaking with solutions being replaced with fresh solution after 24 hrs.
Once crosslinking was completed, plugs were washed 3 times for 60 min and once overnight in
300 mL of distilled water. They were then sterilized under gentle agitation in 50 mL tubes
containing a 40 mL solution of ECA hypochlorous acid dissolved in distilled water at 100 mg/ml
and filtered using a 0.22 µm filter. Sterilization took place over 4 hrs with one solution change
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at the 2 hr mark. Grafts were then washed 3 times for 60 min and once overnight in 50 mL of
sterile PBS. Finally, the sterilized plugs were refrigerated at 4℃ in sterile PBS with 1%
antibiotic-antimycotic mixture until they are ready for implantation.
3.2.2

Rabbit Model
All animal experiments were approved by MSU’s IACUC (Protocol # IACUC-16-357)

board. This animal study involved 16 healthy male New Zeeland White (NZW) rabbits.
Rabbits were pre-medicated with an injection of Ketamine 15 mg/kg, Dex-domitor 0.125 mg/kg,
Butorphanol 0.2 mg/kg, and Glycopyrrolate 0.01 mg/kg (combined and given subcutaneously
with a single syringe) with anesthesia being induced and maintained with isoflurane in oxygen
following endotracheal intubation. One randomly selected hind leg was clipped and prepared for
aseptic surgery. The stifle joint was accessed with a parapatellar incision and lateral dislocation
of the patella. A full-thickness defect located in the central portion of the patellofemoral groove
was created using the Smith and Nephew Mosaicplasty Grafting instrumentation set that matched
to the diameter of the graft (Ø 3.5mm) and length of the graft (range 6-10 mm). The defect was
then filled with a randomly selected graft that was an uncrosslinked control (n=3), a crosslinked
genipin (n=5), a crosslinked EGCG (n=5), or left as an empty control defect (n=3). The grafts
were then tamped into place so that the surface was flush with the surrounding cartilage. The
incisions were then closed in layers and the rabbits were observed until they finished recovering
from anesthesia. Rabbits were then monitored for 4 months and euthanized at the end of the time
period.
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3.2.3
3.2.3.1

Evaluation
Graft Characterization
The frozen decellularized (n=8) and control plugs (n=8) for biochemistry were

lyophilized and the cartilage was separated from the bone followed by a measurement of both
tissues’ dry weight. Each sample was then digested in papain buffer (pH 6.5) for 24 hrs at 60°C.
The papain digested samples were then centrifuged at 10,000 g for 3 min. DNA was quantified
from 50 uL of each sample using Hoechst dye, and fluorescence was measured on a GloMax Jr.
DNA content was calculated using a standard curved created from Calf thymus DNA. Next, 115 uL of the papain digested samples were used to calculate GAG by quantification using DMB
dye. Standards were made by adding chondroitin sulfate at volumes of 0, 3, 6, 9, 12, and 15 μL
to a 96-well. Next, 1-15 μL of papain solution from the samples was transferred to the 96-well
plate, starting with a small volume for the first reading, and then increased for subsequent
readings. All standard and experimental wells were brought to a final total volume of 15 μL
using PBE buffer. Then 250 μL of DMB was then added to each well and the absorbance was
measured at 530 nm and 590 nm as quickly as possible using a spectrophotometer. Dilution
factors of the samples were adjusted until the optical density at 530nm was between 0.3-0.4.
Sample readings were compared to a standard curve created from chondroitin sulfate to
determine the final GAG content. Lastly, 25 uL of each papain digestate and hydroxproline
standard was combined with 50uL of 2 N NaOH in a screw-cap vial and hydrolyzed by
autoclaving at 120°C for 20 min. Hydroxyproline content was determined using the
Chloramine-T assay. All samples were read at 550 nm and hydroxyproline content of the
samples were determined using the developed standard curve. Collagen content was determined
from the assumption that 12.5% of collagen is hydroxyproline, while taking the loss of weight
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due to the reduction of GAG into consideration. A two-sample t-test (α=0.05) was then used to
compare the control tissue and decellularized tissue.
3.2.3.2

Rabbit Model Evaluation
After euthanasia, lateral radiographs were taken of the rabbits’ joints. Following the

radiographs, joints were opened and blindly evaluated by Dr. Steven Elder, Dr. Alan Butler MD,
and Dr. Ryan Butler DVM using a macroscopic scoring scale (Table 3.1) designed for this study
that evaluated intra-articular adhesion, articular surface restoration, the erosion of cartilage, and
graft integration. The joints were dissected and fixed in 10% neutral buffered formalin in
preparation for histology. The slides were stained with H&E and Fast Green & Safranin O, and
scored using a scoring system designed specifically for the evaluation of OCXG (Table 3.2) by
Dr. Steven Elder and Dr. Jim Cooley DVM. Statistical differences will be measured using oneway ANOVA for macroscopic and microscopic scoring.
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Table 3.1

Macroscopic Scoring Table for OCXGs
Category

Grade

I. Intra-articular Adhesion
None

2

Minimal (Fine, Loose fibrous tissue)

1

Major (thick, dense fibrous tissue)

0

II. Restoration of articular surface contour
Complete

2

Partial

1

None

0

III. Erosion of Cartilage
None

2

Graft only

1

Graft and adjacent normal cartilage

0

IV. Integration with adjacent cartilage
Complete

2

Partial

1

None

0

V. Appearance of cartilage
Translucent

2

Opaque

1

None

0

The best possible score is 10 with 0 being the worst.
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Table 3.2

Microscopic Scoring Table for OCXGs
Category

Grade

I. Graft subsidence
None

2

< 1mm

1

> 1mm

0

II. Tissue at articular surface
Only xenograft cartilage

2

Xenograft cartilage overgrown <50% by rabbit cartilage/fibrocartilage

1

Xenograft cartilage overgrown >50% by rabbit cartilage/fibrocartilage

0

III. Integration of xenograft and rabbit articular cartilage
Present

2

Absent

0

IV. Xenograft chondrolysis and replacement
Severe

3

Moderate

2

Mild

1

None

0

V. Replacement of xenograft bone by rabbit bone
> 67%

2

> 33% and ≤ 67%

1

≤ 33%

0

VI. Bone Marrow
> 50% of marrow space occupied by cells*

2

< 50% of marrow space occupied by cells*

1

Poorly cellularized / adipose tissue

0

Best possible score is 13 with 0 being the worst, * including undifferentiated mesenchymal cells,
osteoclasts, and osteoblasts, bone marrow.
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3.2.4

Statistical Analysis
Quantitative data was analyzed using IBM SPSS Statistics 24.

3.3

Results

3.3.1

Biochemistry
The results from the graft characterization biochemical data can be seen in Table 3.3.

The decellularization showed a statically significant reduction of the DNA between the bone and
cartilage samples with the reduction of DNA in the decellularized tissue being 52% and 45%
respectively. The only other statistically significant change was seen in the GAG content of the
cartilage samples with a reduction of 71%.
Table 3.3

Biochemistry Results

Cartilage
Control
Cartilage
Decellularization
Bone
Control
Bone
Decellularization

DNA
Content
Normalized to
Dry Weight
(ng/mg)

GAG Content
Normalized to
Dry Weight
(µg/mg)

Collagen
Content
Normalized to
Dry Weight
(µg/mg)

640.1 ± 185.8

283.3 ± 82.3

111.7 ± 56.8

350.8 ± 80.7*

164.0 ± 29.2*

150.7 ± 35.2

67.6 ± 22.4

1.42 ± 0.67

-

32.7 ± 3.1*

1.10 ± 0.48

-

*Denotes a statistical difference (α=0.05) between a control and a decellularization group.
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3.3.2

Rabbit Model
There were no complications with the surgeries of the animals. During the 4-month

observation period, only one rabbit in the genipin group was reluctant to bear weight on its leg
for 2 weeks after surgery. This rabbit was later excluded from analysis due to having a
dislocated patella. The results from the macroscopic evaluation (Table 3.4) showed that all graft
groups were statistically different (α=0.05) and preformed worse than the empty defect control.
To help delineate more between the groups, the appearance score was removed in a second
review of the macroscopic scoring. No notable differences were seen in the median score values
between different graft groups with all grafts scoring a 6.0 or higher. Only the EGCG group had
a statistical lower difference when compared to the empty defect. The microscopic scoring
(Table 3.5) of the grafts showed no statistical difference between the mean scores of the
uncrosslinked, EGCG, and genipin graft groups. The radiographs (Figure 3.1) confirmed the
microscopic scoring showed similar levels of graft integration into the native bone. The FG &
SO (Figure 3.1) staining showed major collagen loss in the uncrosslinked grafts, some loss in the
EGCG grafts, and minor loss in the genipin grafts.
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Table 3.4

Macroscopic Scoring of Rabbit Joints

Regular Scoring
Mean
Median
Empty
10.67 ± 1.23
11.0
Uncrosslinked
7.67 ± 1.58
8.0*
EGCG
7.00 ± 1.51
7.0*
Genipin
7.58 ± 1.68
7.5*
Without Appearance Score
Mean
Median
Empty
8.444 ± 0.88
8.0
Uncrosslinked
6.111 ± 1.54
6.0
EGCG
6.467 ± 1.6
6.0*
Genipin
6.667 ± 1.30
7.0
*Designates a significant difference (α=0.05) with respect to empty control
Table 3.5

Microscopic Scoring of Grafts
Microscopic Scorings
Mean

Uncrosslinked

8 ± 2.65

Median
9

Genipin

5.75 ± 0.95

5.5

EGCG

5.4 ± 1.67

5
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Figure 3.1

Collage of the Grafts’ Gross Morphology, Radiographs, H&E, and FG & SO
Staining

55

ID

Photo

Radiographs

H&E

2894
Genipin

2895
Genipin

2889
EGCG

2892
EGCG

2898
EGCG

2899
EGCG

2900
EGCG

Figure 3.1 (continued)
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FG & SO

3.4

Discussion & Conclusion
The final goal of our research is to develop an osteochondral xenograft alternative to

autografts and allografts that are used in the OAT surgery to repair osteochondral lesions that
will progress into osteoarthritis. In our previous work, we have explored different approaches to
crosslinking the collagen matrix of the decellularized scaffolds using the natural occurring
crosslinking agents genipin, proanthocyanidin, and EGCG in comparison against glutaraldehyde
, and found that genipin and EGCG were viable options for crosslinking60. In two following
studies, we further explored the crosslinking ability and in vitro biocompatibility of EGCG and
genipin with both studies finding that natural crosslinkers were suitable for stabilization of an
OCXG71,72. The main objective of this study was to assess the viability of both crosslinkers in an
in vivo rabbit model and try to investigate whether genipin or EGCG is a more advantageous
crosslinking agent to pursue for further studies.
This initial step in the evaluation was to characterize the effectiveness of the
decellularization process. Decellularization allows for the removal of the antigens from the
xenograft, which is needed because foreign antigens within the recipient’s body will lead to an
inflammatory response causing graft rejection, slower healing, or slower graft integration. The
largest antigen that needs removal from our scaffold is DNA. Residual DNA can lead to chronic
inflammation, scarring, fibrosis, and encapsulation of the graft. Crapo et al.69 recommended that
decellularization should achieve a DNA reduction to a concentration of less than 50 ng per mg of
dry ECM. The reduction of DNA for our scaffolds was only 45% and 50% in cartilage and bone
respectively with cartilage having a 350 ng/mg dry weight and bone having a 32.7 ng/mg dry
weight. The bone met the standard, but cartilage was very far from meeting the standard. This
lack of thorough decellularization could explain why the empty controls had a slightly better
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macroscopic appearance score. The DNA could have caused an immune response that slowed
the integration of the graft and the healing of the defect.
The decellularization process is not perfect and it does have drawbacks associated with it.
The main drawback is the reduction of the mechanical strength of the cartilage in the
osteochondral graft. It has been seen that the aggressive decellularization process can cause
destruction of the collagen matrix of the ECM leading to a major loss in the mechanical strength
of the graft. Alternatively, decellularization also causes loss of GAG molecules from the ECM,
but while it reduces the mechanical strength of the tissue it does have benefits. It has been
suggested the loss of GAG from the tissue will reduce the chance of antigen rejection of the graft
and provide the native cells with an easier route to infiltrate the graft for quicker integration into
the native tissue. The results showed that our grafts reduced the GAG in the cartilage phase by
71% while showing no significant difference in the amount of collagen left in the ECM. These
results align with the previous need for reducing the loss of collagen and removing some of the
GAG to promote integration into the tissue. Overall, the decellularization of the grafts worked
for the bone interface but was lacking in the reduction of DNA in the cartilage interface
suggesting an opportunity for future improvements.
The next step of graft evaluation was to judge how well the two different grafts worked in
an in vivo rabbit model. The hope of this animal study was to determine if either of the
crosslinking agents, genipin or EGCG, was more advantageous to use for the graft. All grafts
did not show any signs of acute immune rejection from joint implantation and radiographs
showed no problem with the bone phase integrating into the native tissue. Macroscopic scoring
showed the cartilage phase of the grafts preformed slightly worse than the empty defect when
scoring included the appearance score. After the original scoring was analyzed, it was decided to
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remove the appearance score that took account the color of the cartilage from the macroscopic
scoring because the color of the cartilage in the graft portion of the EGCG and genipin
crosslinked scaffolds still retained the characteristic dark color from the chemical crosslinking.
This did alter the macroscopic scoring so only the EGCG grouped had a statistical difference that
was lower than the empty controls. The microscopic scoring for graft integration was in line
with the macroscopic scoring showing that the grafts had no major difference in the way they
performed. The FG & SO staining showed that there was a difference in the washout of collagen
from the graft overtime with the uncrosslinked grafts showing significant loss, EGCG having
moderate loss, and the genipin grafts showing very minimal loss which was remarkably similar
to the empty defects. The histology of the empty defects also had large gaps bellow the repair
site showing that new bone still had not formed suggesting that the defect may not be as
mechanically stable as grafted defects.
The rabbit study did have the grafts underperforming the empty defect slightly in the
cartilage phase of the repair, which could be due to a few reasons. First, rabbits have a strong
ability to repair cartilage damage to the joint compared to other species of animals, so natural
defect repair might be more efficient than scaffold mediated defect repair unless the defect is of a
critical size65,73. The literature on critical size defects for osteochondral rabbit defects does vary
slightly. One study suggest that an Ø 3 mm defect is a critical size65, while a second study
showed near recover of an Ø4 mm defect at 4 months along with a full recovery of a Ø 3 mm
defect 74. This would mean the Ø 3.5mm defect used in this study would still have a good
chance of making an unassisted recovery. The second possibility for underperformance of the
graft’s cartilage phase could be due to DNA not meeting the 50 ng per mg standard, which in
turn slowed the healing speed due to a small immune response to the presence of antigens. The
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grafts may have underperformed in cartilage phase, but it did appear to excel in bone phase
showing more filling of the defect when compared to the empty control. When directly
comparing how well the different crosslinkers preformed against each other it appears that the
genipin performed slightly better than the EGCG by having higher scores with a smaller standard
deviation, but it was not high enough to make a statistic difference between the two except in the
case of EGCG under preforming compared to the empty defect.
In conclusion, there were no major complications with the implantation of the crosslinked
OCXGs but there is still future work to be done in removing the remaining DNA from the grafts.
This DNA reduction to the 50 ng per mg may be needed when moving to a larger animal model
due to the fact cartilage regeneration in rabbits is more forgiving than other animal models65,73.
The head-to-head comparison of the genipin and EGCG grafts showed only one difference in the
two when they were compared to the macroscopic scoring of the empty defect, which EGCG
performed the worst. With this performance and the slightly higher scores with a lower
deviation, genipin was chosen for further investigation in different animal studies. Moving
forward, future research needs to be planned around reducing DNA in the grafts with a focus on
genipin in a larger animal study.
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CHAPTER IV
LONG-TERM GENIPIN-CROSSLINKED OCXG EFFICACY STUDY
4.1

Introduction
In the previous study, OCXGs were successfully crosslinked using genipin and EGCG.

These crosslinked OCXGs had no major complications with implantation in the rabbit model and
the crosslinking improved the performance of the graft. Genipin was recommended for future
work over EGCG by a slight margin but, other unpublished work in our research group did give
a more definitive answer. When grafts that were crosslinked with high concentrations of EGCG
where implanted subcutaneously in mice they caused hepatoxicity and acute liver failure which
matched research by Patel et al75. This new information help solidify genipin as the chosen
crosslinker for the OXCG. The goal of this study had two objectives: the first objective was to
determine how our crosslinked OCXGs would perform in a large animal model and the second
objective was to evaluate how a higher and lower degree of crosslinking would affect
performance of the OCXGs.
The large animal model chosen for this study was the goat, which is a well-known model
for the partial and full thickness osteochondral defects. Goat stifle joints are anatomically very
close the human knee and the closest in size to human. The stifle joint cartilage is slight smaller
in thickness than human cartilage, but this should not matter with our OCXG. The subchondral
bone is similar to humans with respect to structure, mineral composition, bone remodeling rate,
and metabolic rate which should help yield valid results for the bone interface of the graft. Goats
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can also easily be returned to pasture together after a short recovery in their pens, which will
allow for the joint to be exercised more. Two problems with goats are the difficulty in
anesthetizing them and finding a large number of older animals because they need to reach
skeletal maturity which requires at least 2 years. Luckily, we were able to find a convenient
source of skeletally mature goats at the time of the study and our veterinary anesthesiologist Dr.
Natalini had considerable experience anesthetizing goats previously39,64.
The second goal of the study was to investigate how the difference between a high and
low degree of crosslinking would affect the implanted OCXG. In published work from our lab
group, we investigated how changing the concentration genipin affected the degree of
crosslinking using concentration of 0.1%, 0.02%, and 0.004% wt/vol and varying soaking
durations for 24, 48, and 72 hrs. This experiment generated a wide a range of crosslinking
degrees from ~45% to ~90%. Increasing the concentration of genipin directly raised the degree
of crosslinking, while soaking time only increased the crosslinking degree at a lower genipin
concentration between 24 and 48 hrs. The increase in genipin concentration and degree of
crosslinking increased the compressive modulus and the resistance to degradation by
collagenase. Increasing the concentration led to radial shrinkage and an increase in the
coefficient of friction. Finally, autologous chondrocytes displayed little difference in viability ,
attachment, and spreading over the surface of genipin fixed constructs over 6 weeks of in vitro
culture71. For use in our study, crosslinking degrees of ~33% and ~67% would be the most
advantages to test the effects of crosslinking on the performance of the OCXG. In conclusion,
this study investigated how our genipin crosslinked OCXGs would perform in a large animal
goat model and if a higher or lower degree of crosslinking affected the performance of the
OCXGs.
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4.2
4.2.1

Methods
Graft Creation
Porcine stifle joints were collected from a local meat processing plant (Sansing Meat

Service; Maden, MS). Cylindrical osteochondral plugs were harvested (Ø 6 mm by ~ 12 mm)
from the femoral condyles and the patellofemoral grooves using the Smith & Nephew
osteochondral autograft transfer instrument.
4.2.2

Antigen Removal and Decellularization
The antigen removal and decellularization process had changed since the second rabbit

study in order to achieve a better level of DNA removal. All decellularization steps were done
under orbital shaking at 37℃ unless otherwise stated. Plugs were placed in a solution of PBS, at
room temperature for 1 hr. This was followed by 6 hrs in a 3% hydrogen peroxide solution with
a solution change every 2 hrs. Plugs were then placed for 1.5 hrs in chloroform:methanol (1:1)
and then washed for 30 min in methanol followed by 2 washes in distilled water for 30 min. .
Finally, plugs were incubated for 48 hrs in 10 mM Tris-HCl (pH 7.6), 5 mM MgCl2, 0.5 mM
CaCl2, 2% wt/vol SDS, 0.5 mg/ml DNase I, 0.05 mg/ml RNase, 1 mM PMSF, 1% v/v antibioticantimycotic mixture with a solution change after 24 hrs, which was followed by 3 washes in
distilled water for 1 hr each.
The 24 plugs were split into two groups (n=12): a high degree of crosslinking (HighXL)
of ~67% and a low degree of crosslinking (LowXL) of ~33%. Crosslinking solutions were made
by mixing distilled water with genipin at concentrations of 0.015% for a HighXL and 0.001875%
wt/vol for a LowXL. The two groups were then placed under gentle orbital shaking for 48 hrs in
40 mL of crosslinking solution, with the solution being replaced with fresh solution every 24 hrs.
Once crosslinking was completed, plugs were washed 3 times for 60 min and once overnight in
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300 mL of distilled water. They were then sterilized under gentle agitation in 50 mL tubes
containing a 40 mL solution of ECA hypochlorous acid dissolved in distilled water at 100 mg/ml
and filtered using a 0.22 µm filter. Sterilization took place over 4 hrs with one solution change
at 2 hrs. Grafts were then washed 3 times for 60 min and once overnight in 50 mL of sterile
PBS. Finally, the sterilized plugs were refrigerated at 4℃ in sterile PBS with 1% antibioticantimycotic mixture until they are ready for implantation.
4.2.3

Graft Evaluation
The control plugs (n=5) and decellularized plugs (n=8) were lyophilized and had their dry

weights determined. Each sample was then digested in papain buffer (pH 6.5) for 24h at 60°C.
The papain digested samples were then centrifuged at 10,000 g for 3 minutes. DNA was then
quantified from 50uL of each sample using Hoechst dye, and fluorescence was measured on a
GloMax Jr. Fresh and decellularized tissue were fixed in 10% neutral buffed formalin,
decalcified, trimmed, and embedded in paraffin then cut and stained with Safranin-O, as well as
hematoxylin and eosin.
4.2.4

Experimental Design
The study used 12 goats with 8 female goats weighing ~50 to120 lbs and 4 male goats

weighing ~70 to 155 lbs. One goat was euthanized at the start of the surgeries to acquire fresh
allograft controls (n=6) to compare against the highXL (n=8) and lowXL (n=8). The groups
were paired so that the control group had 3 grafts per side of the right femoral condyle and the
experimental groups had 4 grafts per side of the right femoral condyle. The groups were split so
each experimental group was paired with an allograft 3 times and alternated placement on the
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medial and lateral side at least once. The two experimental groups were paired against each
other 5 times and alternated sides at least two times. The groupings can be seen in Table 4.1.
Table 4.1

Animal Group Table

Animal Eartag
ID

Gender

Weight (lbs)

1
2
3
4
5
6
7
8
9
10
11
12

F
F
F
F
F
F
F
F
M
M
M
M

98
48
49
74
90
91
120
78
98
86
70
154

4.2.5

Lateral

Medial

LowXL
HighXL
HighXL
Allograft
LowXL
HighXL
Allograft
LowXL
HighXL
LowXL
LowXL
HighXL
Allograft Donor
Allograft
HighXL
HighXL
LowXL
HighXL
Allograft
LowXL
Allograft
Allograft
LowXL

Goat Surgery
All animal experiments were approved by MSU’s IACUC (Protocol # IACUC-17-494)

board. Goats were premedicated through an intravenous catheter. Anesthetize was then
maintained by intubation through inhaled anesthetic 1.5% Isoflurane at 3 L/min. Hind limbs
were then clipped and scrubbed to prepare them for aseptic surgery. Then a standard lateral
para-patellar approached was made through the skin, subcutaneous tissue, lateral fascia, and joint
capsule using a #10 scalpel blade, metzanbaum scissors, and a combination of blunt and sharp
dissection. The incision extended from the proximal end of the patella to the insertion of the
patellar ligament on the tibial tuberosity, with hemorrhaging being controlled by the use of
monopolar electrosurgery. The patella and joined tissues were then luxated medially to provide
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access to the distal femoral joint surface. A cylindrical defect (Ø 6 mm by ~ 12 mm deep) was
then created in the central weight bearing areas on the left and right sides of the condyle using
the Smith & Nephew Osteochondral autograft transfer instrument. The defect was then filled
with an acellular porcine xenograft or fresh osteochondral allograft of matching size with the
graft being tamped in place until it was flush with the surrounding cartilage using the same OAT
instrument. Before closure, joints were irrigated with sterile saline, then joint capsule, lateral
fascia, subcutaneous tissue, and skin were then closed in separate layers. The same procedure
was then done to the left stifle joint as a sham operation where the articular surface was not
disturbed. Following surgery male goats were castrated and all goats were monitored until they
recovered from anesthesia. They were observed serval times within the first 24 hrs after surgery
and then at least once a day for the rest of the study. Goat pain was assessed based on the
display of the following behaviors: vocalization, teeth grinding, rapid and shallow breathing,
standing and lying repeatedly, tail wagging, occasionally bleating, displaying neck extension,
dorsal lip curling, kicking, rolling, and hyperventilation 76. Each behavior carried a point value of
1 if present, 0 if absent. The sum of all points comprised the composite pain score. The scale
was interpreted in this fashion: 0 represents no pain; numbers 1 to 3 on the scale represent mild
pain, 4 to 6 moderate pain, and 7 to 10 severe pain. However, any animal that displayed two or
more behaviors indicative of pain was evaluated by a veterinarian who decided whether an
analgesic should be administered. Goats were housed in surgery pens until they fully recovered
from surgery and once recovery was complete, they were sent out to pasture. After 6 months had
passed from the initial surgery goats were euthanized and joints were evaluated.
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4.2.6

Goat Evaluation
Goats were observed at least once daily for pain and abnormalities. A week from

euthanize goats were recorded in the pasture moving and running freely to assess gait using a 5
point scale developed by Deeming et al77 (Table 4.2), with scoring being done by Mark Mosher.
After euthanasia, the goats had their left and right hind legs radiographed, followed by the
opening of the joints for macroscopic inspection and grading by Dr. Steven Elder and Dr. Ryan
Butler according to the macroscopic scoring table (Table 4.3). The distal femurs were then
extracted, wrapped in saline, put on ice, and transported back to the biomechanics lab for
mechanical testing. Before mechanical testing the femoral condyles were trimmed to the growth
plate and cut in half separating the lateral and medial sides of the condyle for a more secure fit in
the testing apparatus. After preparation, samples were loaded into a rotating vice to allow the
indenter to apply its force normal to the tissues articular surface, an example of this is seen in
Figure 4.1. Once secured, the Mach-1 Micromechanical Test System was outfitted with a Ø 2
mm flat-ended cylindrical indenter connected to a 10 N load cell. The indentured was lowered
until contact was found and a 0.05 N tare load was applied. Then the indenter was moved 100
μm at a rate of 1 mms-1 and the load was monitored until the relaxation rate of less than 0.005
N*min-1. Throughout the test, samples were kept wet with PBS. The lateral and medial side of
each joint had two measurements: the defect/graft area and an area directly adjacent to the
defect/graft. Once mechanical testing was completed samples were fixed in 10% neutral buffed
formalin. Samples were then decalcified, trimmed, and embedded in paraffin from there sagittal
sections were cut and stained with toluidine blue and hematoxylin and eosins. Sections were
then evaluated by Dr. Alicia Olivier.
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Table 4.2

5-point Goat Gait Scoring

Scoring

Assessment Criteria

Score: Description

Limp

Identified
Affected Leg

Weight
Bearing

Moving
Forward

Head
Nod

1: Normal Gait

No

N/A

Yes

Yes

No

2: Uneven Gait

No

No

Yes

Yes

No

3: Mildly Lame

Yes

Possibly

Yes

Yes

No

4: Moderately
Lame

Yes

Yes

Reluctant

Reluctant

Possibl
y

5: Severely Lame

Yes

Yes

Unable

Unwilling or
Unable

Yes
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Table 4.3

Macroscopic Scoring Table
Category

Score

Cartilage
Normal

0

Surface roughening

1

Fibrillation and fissures

2

Small erosions down to subchondral bone (<5 mm diameter)

3

Larger erosions down to subchondral bone (>5 mm diameter)

4

Osteophyte
Normal

0

Mild osteophyte development (<2 mm outgrowth or < 20% of joint margin)

1

Moderate osteophyte development (2–4 mm outgrowth or 20–50% of joint
margin)

2

Large osteophyte development (>4 mm outgrowth or >50% of joint margin)

3

Synovium
Normal – opal white, semitranslucent, smooth, with sparse well defined blood
vessels

0

Slight – focal involvement, slight discoloration, visible fibrillation/thickening,
notable increase in vascularity

1

Mild – diffuse involvement, slight discoloration, visible fibrillation/thickening,
notable increase in vascularity

2

Moderate – diffuse involvement, severe discoloration, consistent notable
fibrillation/thickening, moderate vascularity

3

Marked – diffuse involvement, severe discoloration, consistent and marked
fibrillation/thickening, marked synovial proliferation with diffuse
hypervascularity

4

Severe – diffuse involvement, severe discoloration, consistent and severe
fibrillation, thickening to the point of fibrosis, severe proliferation and
hypervascularity

5
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Figure 4.1

Example of Indentation Testing Setups

A and B show how the vice could be adjusted to different angles to provide a normal force for
the indenter.

4.3
4.3.1

Results
Graft Evaluation
The decellularization process reduced the DNA content of the cartilage interface by

~87.5% with an average of 346.2±64.8 ng/mg dry weight remaining (Table 4.4).
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Table 4.4

DNA Content
Average DNA
Content
(ng/mg Dry Weight)

4.3.2

Control

2778.2 ± 294.6

Decellularization

346.2 ± 64.8

Gait, Gross Appearance, Radiology, and Histology Evaluation
Goat gait evaluation was done a week before the end point and goats were video recorded

walking, trotting, and running in their pasture. The recordings of the goats were then reviewed,
evaluated, and scored using the 5-point scoring system. The lateral and medial scores of each
goat’s gait contained differences so they were combined to show a total score in Table 4.5. The
high crosslinking graft had slightly worse results at a score of 2.5 but did not have any statistical
difference from the other graft groups due to the high standard deviations.
There were no statistical differences between the Allograft, LowXL, and HighXL grafts
in the scoring of the gross appearance (Figure 4.2). This was due to the allograft and both
crosslinking groups having a large amount of variance in the groups. This would have been ideal
for the evaluation of experimental groups, but all the grafts performed poorly overall leading to
bad results. All types of grafts scored below the halfway grade in their cartilage evaluation
(Table 4.6). The osteophyte grading had a poor grading ranging from moderate to severe (Table
4.7). The synovium grading showed most joints having moderate synovitis (Table 4.8).
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The evaluation of the end point radiographs (Figure 4.3) indicated that the bone section
of the grafts had been or were in the process of resorption and integration with the bone of the
goat. The joint spaced showed progression of osteoarthritis: high amounts of debris within the
joint space, narrowing of the joint space, loss of cartilage from the articular surface, osteophytes,
and fibrous tissue. The radiographs were consistent with the evaluations of the gross anatomy
and gait.
Due to the degradation of many of the joints, only a few selected high and low
crosslinked grafts were used for histology (Figure 4.4). The histology matched with the
radiographs showing a decent integration and reabsorption of bone portion of the grafts. They
aligned with the gross appearance and radiographs where cartilage integration was incomplete
with partial ingrowth or growth of fibrocartilage over the surface of the graft.

Table 4.5

Total

Goat Gait Scoring
Group

Median

Averages

Standard
Deviation

Allograft

2

2.2

±1.30

LowXL

2

2.13

±0.99

HighXL

2.5

2.75

±0.89
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Figure 4.2

Goat Joint Gross Appearance

Table 4.6

Cartilage Macroscopic Scoring

Total

Lateral

Medial

Group

Median

Average

Standard
Deviation

Allograft

3

2.83

±1.34

LowXL

4

3.38

±0.81

HighXL

3.5

3.19

±0.91

Allograft

3

2.5

±1.64

LowXL

4

3.25

±1.04

HighXL

3.5

3.13

±0.99

Allograft

3.5

3.17

±0.98

LowXL

3.5

3.5

±0.53

HighXL

3.5

3.25

±0.89
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Table 4.7

Total

Lateral

Medial

Table 4.8

Total

Osteophytes Macroscopic Scoring
Group

Median

Average

Standard
Deviation

Allograft

2

1.75

±1.06

LowXL

2

2

±0.89

HighXL

3

2.19

±0.98

Allograft

2

1.83

±0.75

LowXL

1.5

1.75

±0.92

HighXL

3

2.38

±0.92

Allograft

2

1.67

±1.37

LowXL

1.5

2.25

±0.89

HighXL

2

2

±1.07

Synovium Macroscopic Scoring
Group

Median

Average

Standard
Deviation

Allograft

2.5

2.5

±1.62

LowXL

2

2.06

±1.39

HighXL

3

3.06

±1.39
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Figure 4.3

Goat Right Knee Endpoint Radiographs

A yellow line indicates the difference between the lateral and medial side
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Figure 4.4

4.3.3

Goat Histology

Mechanical Testing
The single ramp stress relaxation data was used to calculate the stiffness (N/mm) for the

lateral and medial sections of each group separately (Table 4.9, Figure 4.5, Figure 4.6) and then
with both lateral and medial portions of each group combined for a total grouping (Table 4.10,
Figure 4.7). The lateral and medial control, medial allograft, and lateral high crosslinking groups
had their extreme outliers removed from their respective data sets to better evaluate for statistical
significance. Even with the extreme outliers removed there was a high level of variance in each
group, so the median was chosen over the average for comparison of the graft and cartilage
stiffness. The only group that had any significant difference was the lateral allograft from the
lateral control group where the allograft had the lowest stiffness of all groups. The general trend
was the lateral side of the condyle displayed a higher stiffness than the medial side.
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Table 4.9

Median Stiffness

Graft

Control

Allograft

Low
Crosslinking

High
Crosslinking

Indentation
Location

Median Stiffness
(N/mm)

Standard
Deviation

Lateral *

21.09

±9.76

Medial *

12.32

±6.72

Lateral A

8.73

±2.51

Adjacent to
Lateral Graft

14.74

±8.20

Medial *

12.59

±7.13

Adjacent to
Medial Graft

9.55

±4.27

Lateral

12.08

±7.95

Adjacent to
Lateral Graft

16.24

±4.41

Medial

11.13

±8.47

Adjacent to
Medial Graft

9.34

±2.71

Lateral *

17.06

±8.47

Adjacent to
Lateral Graft

14.13

±6.66

Medial

14.06

±8.00

Adjacent to
±9.28
17.67
Medial Graft
* Extreme outliers were removed, A shows a statistical difference with respect to the control
(α=00.5)
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Table 4.10

Median of Combined Lateral and Medial Stiffness

Graft

Indentation
Location

Median
Stiffness
(N/mm)

Standard
Deviation

Control

Graft *

15.23

±9.70

Graft *

8.73

±4.96

Adjacent to
Graft

11.71

±6.77

Graft

11.41

±8.10

Adjacent to
Graft

11.63

±4.98

Graft *

17.06

±8.21

Adjacent to
Graft

14.13

±7.33

Allograft

Low
Crosslinking
High
Crosslinking
* Extreme outliers were removed

Figure 4.5

Graph of Lateral Medians

A shows a statistical difference (α=0.05) between groups.
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Figure 4.6

Graph of Medial Medians

Figure 4.7

Graph of the Combined Lateral and Medial Medians
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4.4

Discussion and Conclusion
The goal of our research is to develop an osteochondral xenograft alternative to

autografts and allografts that are used in the OAT surgery to repair osteochondral lesions that
will progress into osteoarthritis. In the previous study we compared the crosslinkers EGCG and
genipin in a rabbit animal model with the use of genipin being the recommendation. Other
unpublished work in our research group did also show that high concentrations of EGCG when
implanted subcutaneously in mice did cause hepatoxicity and acute liver failure which matched
research done by Patel et al75. The goal of this study was to determine two objectives: the first
objective was to determine how our crosslinked OCXGs would perform in a large animal model
and the second objective was to evaluate how a higher and lower crosslinking of the OCXGs
would affect performance.
The first step in evaluation was determining how effective the decellularization step
before crosslinking was in removing antigens. In this animal study, the most concerning antigen
was the porcine DNA remaining in the scaffold. Residual DNA can lead to chronic
inflammation, scarring, fibrosis, and encapsulation of the graft. Crapo et al. 69 has recommended
that decellularization should achieve a DNA reduction to a concentration of less than 50 ng per
mg of dry ECM. In our previous animal model, we were able to remove 45% of the DNA from
the cartilage scaffold, while in this study we were able to remove ~87.5% DNA from the
cartilage scaffold with an average of 346.2 ng/mg dry weight. While this is a large
improvement, we still need to focus on trying to meet the 50 ng/mg standard set for DNA
removal.
The main results of the study were based on the evaluation of the goat’s gait, gross
appearance of the knee, radiology of the join, histology, and mechanical testing. During the gait
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evaluation no goat was immobile and scored a 5. The majority of the animals scored a 2-3 where
one could tell the gait was uneven and could identify a limp on one leg. The high crosslinking
group had the worse score at 2.5 due to it containing two goats scoring a 4 (HighXL/Allograft,
LowXL/HighXL) and had no goat scoring a 1. The two 1 scoring goats had only allograft and
LowXL grafts in them. Though the HighXL preformed the worse, it was not enough to be
statistically significant.
The gross appearance scoring was not able to determine which graft treatment was the
optimal. All grafts were scored below the halfway mark on their cartilage scores with LowXL
preforming the worst and the Allograft preforming the best. The osteophyte scoring had the
HighXL preforming the worst and Allograft preforming the best. Lastly, the scoring of the
synovium had the HighXL preforming the worst and LowXL preforming the best. This would
suggest that the best preforming graft was the allograft, the middle tier performer was the
LowXL, and the worst preforming graft was the HighXL. No final conclusions on the data can
be made since such large standard deviation in each group led to no statistical differences in
them.
The radiograph and histology evaluations were done qualitatively. The radiographs lined
up with the findings from the gait and gross anatomy showing severe damage to the cartilage and
osteophytes in the joints. The radiographs gave a better view of what happened in the bone
section of the grafts. In most cases, the bone section of the grafts had been replaced by
regenerated caprine bone or were in the process of being replaced, which is a positive outcome
from the experiment. The number of joints sent for histology were changed from the original
plan due to the fact the joint surface and graft were missing in some cases, and some
contamination of joints happened after fixation. The new evaluation selected the best joints from
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each group for histology. The histology evaluation showed joint degradation, incomplete growth
of cartilage over the graft, and fibrocartilage growth over the graft surface and lined up with the
evaluation of the gross morphology and radiographs.
The last evaluation was the mechanical testing of the joints. The stiffness (N/mm) was
determined using a single ramp stress relaxation test. The lateral side of the joint had a higher
stiffness when compared to the medial side. The results for the grafts followed the same pattern
for the rest of the data where the high variability in the data led to only one statistical difference
between the groups and the control. The lateral allografts had a lower stiffness than the control
cartilage. The trends were such that we could not draw a definite conclusion, but the HighXL
cartilage median had the largest stiffness, the LowXL had the second highest stiffness, and the
allograft had the lowest stiffness overall.
The combined data showed there was no significant difference between the control and
the experimental groups, which in most cases would be the ideal situation when comparing it to
gold-standard of allograft. But the variance in the data leads to no reliable or definite answer on
which group performed the best in the model, and even if one could be chosen, they all still
performed poorly. Normally, fresh allografts in goats are associated with better results78,79. This
highlights that there was a problem in the experimental design and that it needs to be corrected in
the future. The first problem may be with the design of having two grafts implanted into one
knee. Pallante et al. 78,79 have done two long term 6-12 month studies using fresh and frozen
allografts in alternating medial femoral condyle and the lateral femoral trochlea with no
problems. In the future, we could follow this structure of implantation instead of using both
condyles or we could only focus on one graft per knee. Another issue could have been the
amount of DNA removal from the graft. The amount of DNA left in the grafts could have
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caused a strong immune response, which two xenografts in a joint would have effectively
doubled the amount of foreign present. Also, in future projects it would be advantageous to take
samples of joint synovial fluid in order to monitor increases in the markers for immune
responses.
In conclusion, the experiment did not yield any conclusive results to suggest that the use
of a crosslinked OCXG is feasible or if the percentage of crosslinking matters. Before evaluating
the genipin crosslink OCXG again in this goat model the decellularization process needs to focus
on reducing the DNA concentration to 50 ng/mg dry weight standard. Currently, our lab has
shown that 0.1 hydrochloric acid reduced the DNA content of porcine menisci from 322.7±74.9
ng/mg dry weight down to 20.8±5.0 ng/mg dry weight, which meets the standard. The goat
model also needs to be changed to implant only one graft per knee, so it is easier to isolate graft
rejection. Other future work could expand on other applications of genipin in osteoarthritis
treatment because this study shows that genipin crosslinked OCXG perform poorly when
implanted.
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CHAPTER V
INVESTIGATION OF A COLLAGEN STABILIZING INTRA-ARTICULAR INJECTION TO
PREVENT OSTEOARTHRITIS
5.1

Introduction and Background
The aim of this study was to leverage the knowledge acquired from the development of

the OCXG as an alternate treatment to slow the progression of OA using the crosslinker genipin
and punicalagin which does not crosslink but tightly binds to the collagen type II. Punicalagin is
an ellagitannin found in pomegranates that binds to collagen, suppresses inflammation, and
inhibits collagenase. The literature has shown that when pomegranate juice was delivered orally
to mice it significantly reduced chondrocyte damage and proteoglycan loss in a monoiodoacetate
osteoarthritis model80. In a study by Jean-Gilles et al. 81, punicalagin inhibited type II collagen
degradation in vitro, and reduced inflammation when intraperitoneally injected in an adjuvantinduced arthritis rat model. The cytotoxicity of punicalagin was found to be very low in a study
done by Kulkarni, Kapor, and Aradhya82. Alternatively, Genipin has been known to be cytotoxic
to chondrocytes under certain conditions and concentrations, but work in our lab determined that
a concentration of 4.0 mM did not prove to be cytotoxic to articular cartilage 83–85.
The simplest way to deliver these drugs to cartilage would be via direct intra-articular
(IA) injection. Currently, IA injections are used in the treatment of osteoarthritis with the use of
hyaluronic acid (HA) and corticosteroids (CS). HA is a naturally occurring GAG in the joint
capsule and articular cartilage. In the joint capsule HA forms, a very viscous solution that helps
84

lubricate the joint during motion. In cartilage, HA links proteoglycans together to form large
aggrecans, which hold attracted water creating a turgor in the tissue that helps the tissue resist
high impact loads11. In addition, HA can also function as an anti-inflammatory, anabolic,
analgesic, and has chondroprotective mechanisms. The Food and Drug Administration (FDA)
has approved treatments of HA injections (sodium hyaluronate, Hylan G-F 20, and highmolecular weight hyaluronan) that vary from 1 to 5 injections and if proven successful, the
patient is encouraged to repeat treatment 6 months later. HA injections are considered safe for
many patients but have mixed recommendations for efficacy. HA injections for 24 weeks might
provide pain reduction in mild osteoarthritis of the knee, but it also has a high cost associated
with the treatment. CS injections work by acting directly on nuclear steroid receptors which
interrupt the inflammatory and immune cascades, thus leading to an inhibition of inflammatory
cells, superoxides, metalloproteases, and several inflammatory mediators. There are currently
five FDA approved CS that are used for IA injections: methylprednisolone acetate; triamcinolone
acetate; betamethasone acetate and betamethasone sodium phosphate; triamcinolone
hexacetonide; and dexamethasone. IA injections of CS are mainly used to treat acute and
chronic inflammation associated with an osteoarthritis flare-up by providing a short term
reduction of pain in moderate to severe cases 86–88.
Along with the current set of injections there are a few emerging therapies that are under
investigation. The two most promising experimental IA injections are botulinum toxin type A
(BTA) and platelet rich plasma (PRP). BTA is a potent neurotoxin produced by the bacterium
Clostridium botulinum that inhibits the release of acetylcholine into the synaptic cleft. The exact
mechanism of action BTA uses to reduce osteoarthritis pain is currently unclear, but it is
theorized that BTA suppresses the secretion of neurotransmitters to directly decrease peripheral
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sensitization and indirectly decrease central sensitization that osteoarthritis pain works through.
In clinical studies BTA has proven to show statistical significance in reducing pain associated
with osteoarthritis. Alternatively, PRP is an autologous material produced by centrifugation of
the blood to obtain a highly concentrated sample of activated platelets in a small volume of
plasma. These activated platelets aid in tissue healing and regeneration by releasing several
growth factors. Preliminary findings indicate that PRP has promising uses for relieving pain,
improving knee function, and improving patient quality of life, but there is no supporting
evidence that PRP will reverse tissue damage done by osteoarthritis 86–88.
The current IA injection treatments only focus on symptom relief. They may reduce
inflammation, swelling, pain, and increase range of motion, but they do not slow the progress of
osteoarthritis in the joint. This is where our IA injection of genipin and/or punicalagin will differ
from the current technology. Early damage in OA is due to the cleavage and denaturing of
collagen type II in the matrix by collagenase. This collagen damage starts from the surface of
the articular cartilage and works deeper into the tissue over time causing a full depth focal lesion
and proteoglycan loss89,90. We theorize that if we can crosslink or bind the surface type II
collagen with genipin or punicalagin then it will slow down the progression of OA. Stabilization
can be accomplished by genipin through powerful covalent crosslinks between free primary
amine groups on lysine and hydroxylysine residues of the collagen molecule91. Punicalagin uses
a separate mechanism by binding to type II collagen through hydrogen bonds, π-π interactions,
and electrostatic interactions81. We hypothesized that a short duration exposure during IA
injection of genipin and/or punicalagin will be able to protect and slow this surface degradation
by stabilizing the type II collagen in the ECM and inhibiting collagenase differing from the
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current symptom-treating IA injections. We plan to test this collagen stabilizing IA injection in
vivo using a rat model.
This was a pilot study with unknown group variance and was limited by budgetary
constraints to a total of 9 rats. To account for observed variability between rats, the group
sample size of 3 was chosen to cover 1 control group and 2 experimental groups and was in line
with experimental groupings used during in vitro testing. The model for inducing osteoarthritis
is different than previous models because it was induced with a chemical agent, monosodium
iodoacetate (MIA), rather than by direct mechanical damage to the tissue. MIA induces arthritis
by inhibiting glyceraldehyde-3-phosphatase dehydrogenase, which kills chondrocytes by
interrupting the glycolysis cycle of the cell. The death of chondrocytes cause lack of upkeep in
the ECM, leading it to degenerate along with the subchondral bone which induces OA92–94. This
was chosen over mechanical inducement of OA because it would allow for relatively low
disruption of the joint capsule making it easier to access the joint for injections. Also, it had the
benefit of being done by the supplier of rats (Charles-Rivers) at a cheaper price then preforming
the surgery or injection locally.
5.2
5.2.1

Methods
Rat Model
All animal experiments were approved by MSU’s IACUC (Protocol # IACUC-17-702)

board. A total of 9 male rats weighing between 226 to 250 grams were obtained from CharlesRivers. Before shipment from Charles-Rivers the rats had osteoarthritis chemically induced with
and injection of MIA in left/right knee. One week after the inducement of arthritis the rats were
split into three different groups containing 3 rats per group. Each group received a different
semiweekly injection: 10 mg/ml punicalagin and 0.9 mg/ml genipin (n=3) or 10 mg/ml
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punicalagin (n=3) in the two experimental groups and a sham injection of phosphate buffered
saline in the control group (n=3). The rats received injections for 4 weeks for a total of 8
injections for each rat. Injections started 5 days after MIA inducement due to shipping and the
required quarantine after arrival. This small time delay should not have cause gross lesions on
the cartilage, but could have led to necrotic cartilage and loss of chondrocyte cellular detail92.
The solutions were prepared the day of the injection and were suspended in IV saline and then
filter sterilized using a 0.22 µm syringe filter. Before the injection, rats were anesthetized by
boxing with 5% isoflurane and then maintained with a 2% isoflurane and air mixture using a
nose cone. The injection site was prepared by shaving and then cleaning with 4% chlorhexidine
scrub and alcohol. The injection was done using a 03 mL 29G X 1/2 syringe to access the joint
space of the knee through the center of the patellar ligament and injecting 30 uL of solution into
the joint, while the leg was held in maximum flexion. Afterwards, the rat was recovered from
anesthesia and placed back in their cage. Three days after the final injection the rats were
euthanized by carbon dioxide overdose and knee joints were harvest en bloc using a rongeur.
Samples of the heart, blood, kidneys, lungs, liver, and spleen were collected to check for possible
systemic effects of the injection. Tissue samples were fixed in 10% neutral buffered formalin,
imbedded in paraffin for histology and cut into thin sections for histology. All sections were
stained with H&E, while joint sections were additionally stained with fast green & safranin O.
Using the OARSI histopathology instrument the medial tibial plateau was evaluated by Dr.
Alicia Olivier for cartilage degeneration and erosion, with the scoring including matrix loss
width (reported in microns) and cartilage degeneration (0-15 grading scale)95.
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5.3

Results
One rat from the genipin and punicalagin injection group died from complications during

recovery from anesthesia during the third injection. A second rat was removed from the
punicalagin group due to complications from the injection. During the first round of injections,
this rat’s joint was swollen, and the joint capsule was extremely hard to access with the needle
leading to an uncertainty if the treatment was administered properly. The remaining 7 rats over
the 5 weeks showed normal activity and movement during observations, though the control
group did have a slight swelling in their knees compared to the experimental groups. The
histology of the heart, liver, spleen, lungs, and kidneys showed no sign of systemic damage from
any of the injected drugs. The histology from the joints showed that the MIA did induce OA in
the joint, but it was sporadic on the articular surface. The control group showed the most
damage to the cartilage having surface damage and full thickness lesions on the tibia and femur
at their interface (Figure 5.1). This group also had some collagen loss throughout the tissue, with
major loss around the tibia and femur interface and at the femur and patellar interface. The only
chondrocyte loss in this group was around areas of cartilage damage. The punicalagin treatment
had some full thickness damage on the tibia side of the tibia and femur interface with the femur
side only having moderate damage to the articular surface (Figure 5.1). The rest of the femur
cartilage had no sign of damage. There was major collagen loss around the damaged areas of the
cartilage and moderate loss throughout the undamaged areas. The only loss of chondrocytes was
around the damaged areas of the tissue. The histology for the combined genipin and punicalagin
showed only minor to moderate surface damage to the femur, but there were full thickness
defects on the tibia. The majority of cartilage showed major collagen loss throughout the tissue,
especially around the interface of the tibia and femur (Figure 5.1). Also, major loss of the
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chondrocytes in areas of the collagen loss and the tibia and femur interface were seen, and there
were clear lines of chondrocyte loss between damaged and undamaged sites (Figure 5.2). The
damage to cartilage was the worst in the control group, while the combined genipin and
punicalagin showed the least damage. The highest amount of chondrocyte and collagen loss was
seen in the combined genipin and punicalagin, while the least amount of loss was seen in the
control injection group. The results from the OARSI histopathology are displayed in Table 5.1,
with a low matrix loss being ideal and the degeneration scoring having 15 represent the complete
erosion of cartilage and 0 being normal cartilage.

Figure 5.1

Rat Joint Histology

The top images are stained with Fast Green-Safranin O, while the bottom images are in H&E.
The images show the interface of the femur and tibia of the control, punicalagin, and genipin and
punicalagin groups, labeled A, B, and C respectively.
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Figure 5.2

Chondrocyte Damage Line

H&E stain showing a line of chondrocyte loss along the femur in the combined group.
Table 5.1

OARSI histopathology

Injection

Surface (0%)
Matrix Loss
(µm)

Midzone (50%)
Matrix Loss (µm)

Tidemark (100%)
Matrix Loss (µm)

Degeneration
Score

Saline 1

990

156

252

15

Saline 2

2155

1724

1664

15

Saline 3

2144

2144

2144

15

Punicalagin 1

80

0

0

8

Punicalagin 2

945

336

112

9

Genipin &
Punicalagin 1

1249

789

669

15

Genipin &
Punicalagin 2

878

0

153

13
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5.4

Discussion and Conclusion
The goal of this study was to do an initial investigation on the intraarticular injection of

punicalagin and genipin to see if they could effectively slow or stop the loss of cartilage in an
animal model. In Vitro testing has shown positive results using the two different crosslinking
methods. Each method has proven not to be cytotoxic to cultured cells, but in vitro testing can
only give us so much information. In vivo testing allowed us to see if there was any systemic
immunotoxicity related to the use of injectable and see if the dosage would be enough to stabilize
the damaged cartilage matrix before being flushed from the joint. This pilot study used a rat
model that had osteoarthritis chemically induced with MIA. The model was effective for this
pilot study, but it did have a flaw. The MIA inducement of osteoarthritis was not consistent in
the inducement of osteoarthritis. Moving through the depths of the cartilage histology showed
sections with major arthritis damage followed by areas with no damage or chondrocyte loss. In
the future, a mechanical induction of osteoarthritis would be more advantageous to use such as
the medial meniscus transection, which leads to a uniform cartilage damage throughout the
joint96,97. The rats that were excluded from the study were not due to interactions with the
injectable drugs. The first rat was lost during recovery from anesthesia and the second rat had
increased swelling and locking within the joint compared to the other rats before the start of
injections. The swelling of the joint made it difficult to properly inject into the joint capsule and
led to doubt that the rat was receiving the treatment. The remaining rats in the study showed
normal activity and joint movement during the study, with the control groups having slightly
more swelling in the knees compared to the experimental injection groups.
All experimental and control groups showed no sign of systemic rejection in the major
organs from the injection routine, which matched our previous work that showed punicalagin and
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genipin were not cytotoxic in the concentrations that were used for this study85. The group that
suffered from the highest level of tissue loss and damage was the control group where there was
surface damage and full thickness lesions on the tibial and femur sides of the joint. The control
group suffered major losses of collagen and chondrocytes around damaged areas and some loss
of collagen in undamaged areas. The best preforming group in the study was the punicalagin
injection. This group had lower degeneration scores and the smallest loss of the cartilage matrix
in all three zones in the OARSI histological assessment. The combined injection lost more
matrix then punicalagin group but performed better than the control group. In the degradation
scoring the combined group performed as badly as the control group scoring a 15 and a 13 due to
the higher loss of chondrocytes. The trend of lower tissue damage but increased collagen and
chondrocyte loss is a particularly important factor in determining the effectiveness of the novel
crosslinking injections. This trend shows that all joints were suffering from MIA induced
arthritis, which caused the cell death of chondrocytes and normally leads to the destruction of the
ECM and tissue. In this case where cell loss was seen in the experimental groups the ECM and
tissue showed no damage due to the collagen stabilization stopping mechanical degradation.
This shows that the injections did provide some remediation and slowed the progression of
osteoarthritis in the joints and gave proof that the injections were not flushed from the joints
quickly enough to prevent any stabilization. Another important conclusion was that no
cumulative gain in performance was observed by combining genipin and punicalagin. The
OARSI scoring suggests that combining the two drugs does cause an interaction, which leads to
the punicalagin being less effective at the same concentration. This aligns with other in vitro
research done by our lab group which showed there was no additive effect in combining the two
drugs85.
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In summary, the rat MIA induced osteoarthritis model was effective, but was sporadic in
the areas of the joint that showed signs of arthritis. In the future, the MMT model to
mechanically induce arthritis would be a better option. Next, all the novel drugs did not show
any signs acute or systemic immune rejection from the rats. The drugs were able to stay in the
joint capsule long enough to allow for some stabilization in both cases. This stabilization helped
remediate the tissue damage caused by MIA killing the chondrocytes in the cartilage. The
stabilized ECM was able to resist the mechanical damage seen in the control group that caused
full thickness lesions. Also, the study added additional evidence that the two forms of
stabilization do have competing interactions showing punicalagin having lower effectiveness
when combined. In conclusion, this pilot study shows evidence that it would be advantageous to
perform more research on a punicalagin injection, which slowed the progression of osteoarthritis.
Future work would benefit from a study with increased animal numbers and a different model of
arthritis induction.
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CHAPTER VI
SUMMARY
The main goal of this dissertation was to develop a therapy that would slow and stop the
progression of focal lesion before they developed into osteoarthritis. The majority of the
dissertation looked to accomplish this by developing a crosslinked osteochondral xenograft
derived from porcine articular cartilage and bone that could be used in the OAT surgery. The
first aim was to find the most effective decellularization and antigen removal techniques out of 3
different protocols. This aim concluded that none of the three decellularization protocols meet all
the standards: less than 50 ng per mg of dry tissue; full removal of cell nuclei; minimal immune
response in vivo; maintaining the mechanical properties of the osteochondral plug; and maintain
the same calcium; collagen; and GAG content. Even though none of the protocols meet the
standards perfectly, protocol 2 was chosen because it maintained the mechanical strength and
calcium content of the bone interface. This protocol was also more advantageous for use in
future studies because the protocol was simpler and could be quickly altered to be more
aggressive with its DNA removal. The second aim investigated the difference between how well
genipin and EGCG crosslinked the decellularized OCXG and how they performed in a rabbit in
vivo model. Like the previous study, there is a need to lower the residual DNA in the cartilage
portion scaffold to meet the 50 ng per mg standard. Genipin performed better against EGCG and
was chosen as the crosslinker for future studies. The third aim studied the effects of altering the
genipin degree of crosslinking in the graft’s performance in a large animal model using goats.
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The results of the study did not yield any meaningful results due to the large variance in the data
and poor performance in the experimental groups and control groups. This could have been the
fault of poor DNA removal or the experimental design of the goat model. Future work needs to
focus on DNA removal meeting the 50 ng per mg standard for the OCXG, exploring new
crosslinkers, and applying our knowledge on crosslinkers to other applications in cartilage repair.
The last aim of the study used the knowledge gained from the work with genipin to conduct a
pilot study investigating the effects of direct injections of punicalagin and genipin on a rat model
were MIA induced arthritis. The experimental injections did not cause acute or systemic
immune rejection and appeared to slow the progression of osteoarthritis. Combining genipin and
punicalagin did not have an added beneficial effect and it caused a lowering of the effectiveness
of punicalagin which preformed the best. Future work with injectable stabilizers and
crosslinkers using a more comprehensive small animal study looks promising.

96

REFERENCES
1. Barbour KE. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and ArthritisAttributable Activity Limitation — United States, 2013–2015. MMWR. 2017;66(9):246-253.
doi:10.15585/mmwr.mm6609e1
2. Learn More Arthritis Facts - Arthritis by the Numbers Can Help. Living With Arthritis.
Published February 25, 2020. Accessed February 18, 2021. http://blog.arthritis.org/livingwith-arthritis/arthritis-facts-by-the-numbers/
3. Jafarzadeh SR, Felson DT. Updated estimates suggest a much higher prevalence of arthritis
in US adults than previous ones. Arthritis Rheumatol. 2018;70(2):185-192.
doi:10.1002/art.40355
4. Murphy LB, Cisternas MG, Pasta DJ, Helmick CG, Yelin EH. Medical Expenditures and
Earnings Losses Among US Adults With Arthritis in 2013. Arthritis Care & Research.
2018;70(6):869-876. doi:https://doi.org/10.1002/acr.23425
5. Cisternas MG, Murphy L, Sacks JJ, Solomon DH, Pasta DJ, Helmick CG. Alternative
Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US
Population-Based Survey. Arthritis Care Res (Hoboken). 2016;68(5):574-580.
doi:10.1002/acr.22721
6. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the Prevalence of Arthritis and
Other Rheumatic Conditions in the United States, Part II. Arthritis Rheum. 2008;58(1):26-35.
doi:10.1002/art.23176
7. Christiansen BA, Guilak F, Lockwood KA, et al. Non-invasive mouse models of posttraumatic osteoarthritis. Osteoarthritis and Cartilage. 2015;23(10):1627-1638.
doi:10.1016/j.joca.2015.05.009
8. Tissue Engineering. Elsevier; 2008. doi:10.1016/B978-0-12-370869-4.X0001-8
9. Leger DL. Fundamentals of Biomechanics: Equilibrium, Motion, and Deformation. 2nd ed.
(Nordin M, ed.). Springer-Verlag; 1999. doi:10.1007/978-1-4757-3067-8
10. Buckwalter J, Mow V, Ratcliffe A. Restoration of Injured or Degenerated Articular
Cartilage. Journal of the American Academy of Orthopaedic Surgeons. 1994;2(4):192-201.
11. Standring S. Grays Anatomy. 41 edition. Elsevier; 2015.
97

12. Bhosale AM, Richardson JB. Articular cartilage: structure, injuries and review of
management. British Medical Bulletin. 2008;87(1):77-95. doi:10.1093/bmb/ldn025
13. Sophia Fox AJ, Bedi A, Rodeo SA. The Basic Science of Articular Cartilage: Structure,
Composition, and Function. Sports Health: A Multidisciplinary Approach. 2009;1(6):461468. doi:10.1177/1941738109350438
14. Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. Structure and function of aggrecan. Cell
Research. 2002;12(1):19-32. doi:10.1038/sj.cr.7290106
15. Heir S, Nerhus TK, Røtterud JH, et al. Focal Cartilage Defects in the Knee Impair Quality of
Life as Much as Severe Osteoarthritis: A Comparison of Knee Injury and Osteoarthritis
Outcome Score in 4 Patient Categories Scheduled for Knee Surgery. The American Journal
of Sports Medicine. 2010;38(2):231-237. doi:10.1177/0363546509352157
16. Falah M, Nierenberg G, Soudry M, Hayden M, Volpin G. Treatment of articular cartilage
lesions of the knee. International Orthopaedics. 2010;34(5):621-630. doi:10.1007/s00264010-0959-y
17. Guermazi A, Hayashi D, Roemer FW, et al. Brief Report: Partial- and Full-Thickness Focal
Cartilage Defects Contribute Equally to Development of New Cartilage Damage in Knee
Osteoarthritis: The Multicenter Osteoarthritis Study: CONTRIBUTION OF CARTILAGE
DEFECTS TO CARTILAGE LOSS IN OA. Arthritis & Rheumatology. 2017;69(3):560-564.
doi:10.1002/art.39970
18. Venäläinen MS, Mononen ME, Salo J, et al. Quantitative Evaluation of the Mechanical
Risks Caused by Focal Cartilage Defects in the Knee. Scientific Reports. 2016;6(1).
doi:10.1038/srep37538
19. Cole BJ, DeBerardino T, Brewster R, et al. Outcomes of Autologous Chondrocyte
Implantation in Study of the Treatment of Articular Repair (STAR) Patients With
Osteochondritis Dissecans. Am J Sports Med. 2012;40(9):2015-2022.
doi:10.1177/0363546512453292
20. Kellgren JH, Lawrence JS. Radiological Assessment of Osteo-Arthrosis. Ann Rheum Dis.
1957;16(4):494-502.
21. Wright RW, Ross JR, Haas AK, et al. Osteoarthritis Classification Scales: Interobserver
Reliability and Arthroscopic Correlation. J Bone Joint Surg Am. 2014;96(14):1145-1151.
doi:10.2106/JBJS.M.00929
22. Brittberg M. Evaluation of cartilage injuries and cartilage repair. Osteologie. 2000;9(1):1725.
23. ICRS Cartilage Injury Evaluation Package. Published online January 30, 2000. Accessed
March 10, 2020. https://cartilage.org/society/publications/icrs-score/
98

24. Erggelet C, Vavken P. Microfracture for the treatment of cartilage defects in the knee joint –
A golden standard? Journal of Clinical Orthopaedics and Trauma. 2016;7(3):145-152.
doi:10.1016/j.jcot.2016.06.015
25. Bj C. Surgical Management of Articular Cartilage Defects in the Knee. 2009;91(7):14.
26. Tetteh ES, Bajaj S, Ghodadra NS, Cole BJ. The Basic Science and Surgical Treatment
Options for Articular Cartilage Injuries of the Knee. Journal of Orthopaedic & Sports
Physical Therapy. 2012;42(3):243-253. doi:10.2519/jospt.2012.3673
27. Block J, Stiebel M, Miller L. Post-traumatic knee osteoarthritis in the young patient:
therapeutic dilemmas and emerging technologies. Open Access Journal of Sports Medicine.
Published online April 2014:73. doi:10.2147/OAJSM.S61865
28. Ferruzzi A, Buda R, Faldini C, et al. Autologous chondrocyte implantation in the knee joint:
open compared with arthroscopic technique. Comparison at a minimum follow-up of five
years. J Bone Joint Surg Am. 2008;90 Suppl 4:90-101. doi:10.2106/JBJS.H.00633
29. Iwasa J, Engebretsen L, Shima Y, Ochi M. Clinical application of scaffolds for cartilage
tissue engineering. Knee Surgery, Sports Traumatology, Arthroscopy. 2009;17(6):561-577.
doi:10.1007/s00167-008-0663-2
30. Labek G, Thaler M, Janda W, Agreiter M, Stöckl B. Revision rates after total joint
replacement: CUMULATIVE RESULTS FROM WORLDWIDE JOINT REGISTER
DATASETS. The Journal of Bone and Joint Surgery British volume. 2011;93-B(3):293-297.
doi:10.1302/0301-620X.93B3.25467
31. Perera J, Gikas P, Bentley G. The present state of treatments for articular cartilage defects in
the knee. Ann R Coll Surg Engl. 2012;94(6):381-387.
doi:10.1308/003588412X13171221592573
32. Bedi A, Feeley BT, Williams RJ. Management of Articular Cartilage Defects of the Knee:
The Journal of Bone and Joint Surgery-American Volume. 2010;92(4):994-1009.
doi:10.2106/JBJS.I.00895
33. Richter DL, Schenck RC, Wascher DC, Treme G. Knee Articular Cartilage Repair and
Restoration Techniques. Sports Health. 2016;8(2):153-160. doi:10.1177/1941738115611350
34. Torrie AM, Kesler WW, Elkin J, Gallo RA. Osteochondral allograft. Curr Rev
Musculoskelet Med. 2015;8(4):413-422. doi:10.1007/s12178-015-9298-3
35. Tírico LEP, McCauley JC, Pulido PA, Demange MK, Bugbee WD. Is Patient Satisfaction
Associated With Clinical Outcomes After Osteochondral Allograft Transplantation in the
Knee? Am J Sports Med. 2019;47(1):82-87. doi:10.1177/0363546518812420

99

36. Chahla J, Sweet MC, Okoroha KR, et al. Osteochondral Allograft Transplantation in the
Patellofemoral Joint: A Systematic Review. Am J Sports Med. 2019;47(12):3009-3018.
doi:10.1177/0363546518814236
37. Familiari F, Cinque ME, Chahla J, et al. Clinical Outcomes and Failure Rates of
Osteochondral Allograft Transplantation in the Knee: A Systematic Review. Am J Sports
Med. 2018;46(14):3541-3549. doi:10.1177/0363546517732531
38. Kääb MJ, Gwynn IA, Nötzli HP. Collagen fibre arrangement in the tibial plateau articular
cartilage of man and other mammalian species. Journal of Anatomy. 1998;193(1):23-34.
doi:https://doi.org/10.1046/j.1469-7580.1998.19310023.x
39. Oláh T, Cai X, Michaelis JC, Madry H. Comparative anatomy and morphology of the knee
in translational models for articular cartilage disorders. Part I: Large animals. Annals of
Anatomy - Anatomischer Anzeiger. 2021;235:151680. doi:10.1016/j.aanat.2021.151680
40. Schulze-Tanzil G, Silawal S, Hoyer M. Anatomical feature of knee joint in Aachen minipig
as a novel miniature pig line for experimental research in orthopaedics. Annals of Anatomy Anatomischer Anzeiger. 2020;227:151411. doi:10.1016/j.aanat.2019.07.012
41. Chu CR, Szczodry M, Bruno S. Animal Models for Cartilage Regeneration and Repair.
Tissue Eng Part B Rev. 2010;16(1):105-115. doi:10.1089/ten.teb.2009.0452
42. Taylor SD, Tsiridis E, Ingham E, Jin Z, Fisher J, Williams S. Comparison of human and
animal femoral head chondral properties and geometries. Proc Inst Mech Eng H.
2012;226(1):55-62. doi:10.1177/0954411911428717
43. Fermor HL, McLure SWD, Taylor SD, et al. Biological, biochemical and biomechanical
characterisation of articular cartilage from the porcine, bovine and ovine hip and knee. BME.
2015;25(4):381-395. doi:10.3233/BME-151533
44. Chen RH, Kadner A, Mitchell RN, Adams DH. Mechanism of Delayed Rejection in
Transgenic Pig-to-Primate Cardiac Xenotransplantation. Journal of Surgical Research.
2000;90(2):119-125. doi:10.1006/jsre.2000.5864
45. Cooper DKC, Gaston R, Eckhoff D, et al. Xenotransplantation—the current status and
prospects. Br Med Bull. 2018;125(1):5-14. doi:10.1093/bmb/ldx043
46. Cozzi E, Bosio E, Seveso M, Vadori M, Ancona E. Xenotransplantation—current status and
future perspectives. British Medical Bulletin. 2005;75-76(1):99-114.
doi:10.1093/bmb/ldh061
47. Wong ML, Griffiths LG. Immunogenicity in xenogeneic scaffold generation: Antigen
removal vs. decellularization. Acta Biomaterialia. 2014;10(5):1806-1816.
doi:10.1016/j.actbio.2014.01.028

100

48. Cissell DD, Hu JC, Griffiths LG, Athanasiou KA. Antigen Removal for the Production of
Biomechanically Functional, Xenogeneic Tissue Grafts. J Biomech. 2014;47(9):1987-1996.
doi:10.1016/j.jbiomech.2013.10.041
49. Lu T, Yang B, Wang R, Qin C. Xenotransplantation: Current Status in Preclinical Research.
Front Immunol. 2020;10. doi:10.3389/fimmu.2019.03060
50. Sprangers B, Waer M, Billiau AD. Xenotransplantation: Where are we in 2008? Kidney
International. 2008;74(1):14-21. doi:10.1038/ki.2008.135
51. Galili U. Significance of anti-gal IgG in chronic xenograft rejection. Transplantation
Proceedings. 1999;31(1-2):940-941. doi:10.1016/S0041-1345(98)01846-6
52. Robson SC, Esch JSA, Bach FH. Factors in Xenograft Rejection. Annals of the New York
Academy of Sciences. 1999;875(1):261-276. doi:10.1111/j.1749-6632.1999.tb08509.x
53. Kheir E, Stapleton T, Shaw D, Jin Z, Fisher J, Ingham E. Development and characterization
of an acellular porcine cartilage bone matrix for use in tissue engineering. Journal of
Biomedical Materials Research Part A. 2011;99A(2):283-294. doi:10.1002/jbm.a.33171
54. Elder BD, Eleswarapu SV, Athanasiou KA. Extraction Techniques for the Decellularization
of Tissue Engineered Articular Cartilage Constructs. Biomaterials. 2009;30(22):3749-3756.
doi:10.1016/j.biomaterials.2009.03.050
55. Revell WJ, Heatley FW. Functional restoration of an articular surface using a heterotopic
xenograft: biology of host-implant interactions in the canine patella. Biomaterials.
1988;9(2):173-180. doi:10.1016/0142-9612(88)90118-4
56. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate
(EGCG): Mechanisms, perspectives and clinical applications. Biochemical Pharmacology.
2011;82(12):1807-1821. doi:10.1016/j.bcp.2011.07.093
57. Hiraishi N, Sono R, Sofiqul I, et al. In vitro evaluation of plant-derived agents to preserve
dentin collagen. Dental Materials. 2013;29(10):1048-1054. doi:10.1016/j.dental.2013.07.015
58. Somers P, De Somer F, Cornelissen M, et al. Genipin blues: an alternative non-toxic
crosslinker for heart valves? J Heart Valve Dis. 2008;17(6):682-688.
59. Cheng NC, Estes BT, Young TH, Guilak F. Genipin-Crosslinked Cartilage-Derived Matrix
as a Scaffold for Human Adipose-Derived Stem Cell Chondrogenesis. Tissue Engineering
Part A. 2013;19(3-4):484-496. doi:10.1089/ten.tea.2012.0384
60. Pinheiro A, Cooley A, Liao J, Prabhu R, Elder S. Comparison of natural crosslinking agents
for the stabilization of xenogenic articular cartilage. Journal of Orthopaedic Research.
2016;34(6):1037-1046. doi:10.1002/jor.23121

101

61. Wang B, Borazjani A, Tahai M, et al. Fabrication of Cardiac Patch with Decellularized
Porcine Myocardial Scaffold and Bone Marrow Mononuclear Cells. J Biomed Mater Res A.
2010;94(4):1100-1110. doi:10.1002/jbm.a.32781
62. Xie H, Yang F, Deng L, et al. The performance of a bone-derived scaffold material in the
repair of critical bone defects in a rhesus monkey model. Biomaterials. 2007;28(22):33143324. doi:10.1016/j.biomaterials.2007.04.001
63. Oláh T, Michaelis JC, Cai X, Cucchiarini M, Madry H. Comparative anatomy and
morphology of the knee in translational models for articular cartilage disorders. Part II:
Small animals. Annals of Anatomy - Anatomischer Anzeiger. 2021;234:151630.
doi:10.1016/j.aanat.2020.151630
64. Cope PJ, Ourradi K, Li Y, Sharif M. Models of osteoarthritis: the good, the bad and the
promising. Osteoarthritis and Cartilage. 2019;27(2):230-239.
doi:10.1016/j.joca.2018.09.016
65. Cook JL, Hung CT, Kuroki K, et al. Animal models of cartilage repair. Bone Joint Res.
2014;3(4):89-94. doi:10.1302/2046-3758.34.2000238
66. Frenkel SR, Kubiak EN, Truncale KG. The Repair Response to Osteochondral Implant
Types in a Rabbit Model. Cell and Tissue Banking. 2006;7(1):29-37. doi:10.1007/s10561005-0068-0
67. Yoshioka T, Mishima H, Ohyabu Y, et al. Repair of large osteochondral defects with
allogeneic cartilaginous aggregates formed from bone marrow-derived cells using RWV
bioreactor. J Orthop Res. 2007;25(10):1291-1298. doi:10.1002/jor.20426
68. Soltz MA, Ateshian GA. Experimental verification and theoretical prediction of cartilage
interstitial fluid pressurization at an impermeable contact interface in confined compression.
Journal of Biomechanics. 1998;31:927-934. doi:10.1016/S0021-9290(98)00105-5
69. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ
decellularization processes. Biomaterials. 2011;32(12):3233-3243.
doi:10.1016/j.biomaterials.2011.01.057
70. Elder S, Chenault H, Gloth P, et al. Effects of antigen removal on a porcine osteochondral
xenograft for articular cartilage repair. Journal of Biomedical Materials Research Part A.
2018;106(8):2251-2260. doi:10.1002/jbm.a.36411
71. Elder S, Pinheiro A, Young C, Smith P, Wright E. Evaluation of genipin for stabilization of
decellularized porcine cartilage. Journal of Orthopaedic Research. 2017;35(9):1949-1957.
doi:10.1002/jor.23483
72. Elder S, Clune J, Walker J, Gloth P. Suitability of EGCG as a Means of Stabilizing a Porcine
Osteochondral Xenograft. J Funct Biomater. 2017;8(4). doi:10.3390/jfb8040043
102

73. Gregory MH, Capito N, Kuroki K, Stoker AM, Cook JL, Sherman SL. A Review of
Translational Animal Models for Knee Osteoarthritis. Arthritis. 2012;2012:1-14.
doi:10.1155/2012/764621
74. Lietman SA, Miyamoto S, Brown PR, Inoue N, Reddi AH. The temporal sequence of
spontaneous repair of osteochondral defects in the knees of rabbits is dependent on the
geometry of the defect. THE JOURNAL OF BONE AND JOINT SURGERY. 2002;84(4):7.
75. Patel SS. Green tea extract: A potential cause of acute liver failure. WJG. 2013;19(31):5174.
doi:10.3748/wjg.v19.i31.5174
76. Okafor RO, Remi-Adewunmi BD, Fadason ST. Effect of Piroxicam and/or Ascorbic Acid on
Postoperative Pain in Orchidectomised Goats. Journal of Animals. 2014;2014.
doi:10.1155/2014/923170
77. Deeming LE, Beausoleil NJ, Stafford KJ, Webster JR, Zobel G. Technical note: The
development of a reliable 5-point gait scoring system for use in dairy goats. Journal of Dairy
Science. 2018;101(5):4491-4497. doi:10.3168/jds.2017-13950
78. Pallante AL, Görtz S, Chen AC, et al. Treatment of Articular Cartilage Defects in the Goat
with Frozen Versus Fresh Osteochondral Allografts: Effects on Cartilage Stiffness, Zonal
Composition, and Structure at Six Months. J Bone Joint Surg Am. 2012;94(21):1984-1995.
doi:10.2106/JBJS.K.00439
79. Pallante AL, Chen AC, Ball ST, et al. The In Vivo Performance of Osteochondral Allografts
in the Goat Is Diminished With Extended Storage and Decreased Cartilage Cellularity. Am J
Sports Med. 2012;40(8):1814-1823. doi:10.1177/0363546512449321
80. Hadipour‐Jahromy M, Mozaffari‐Kermani R. Chondroprotective effects of pomegranate
juice on monoiodoacetate-induced osteoarthritis of the knee joint of mice. Phytotherapy
Research. 2010;24(2):182-185. doi:10.1002/ptr.2880
81. Jean-Gilles D, Li L, Vaidyanathan VG, et al. Inhibitory effects of polyphenol punicalagin on
type-II collagen degradation in vitro and inflammation in vivo. Chemico-Biological
Interactions. 2013;205(2):90-99. doi:10.1016/j.cbi.2013.06.018
82. Kulkarni AP, Mahal HS, Kapoor S, Aradhya SM. In Vitro Studies on the Binding,
Antioxidant, and Cytotoxic Actions of Punicalagin. J Agric Food Chem. 2007;55(4):14911500. doi:10.1021/jf0626720
83. McGann ME, Bonitsky CM, Jackson ML, Ovaert TC, Trippel SB, Wagner DR. Genipin
crosslinking of cartilage enhances resistance to biochemical degradation and mechanical
wear: GENIPIN PREVENTS CARTILAGE DEGENERATION. Journal of Orthopaedic
Research. 2015;33(11):1571-1579. doi:10.1002/jor.22939

103

84. Lima EG, Tan AR, Tai T, et al. Genipin enhances the mechanical properties of tissueengineered cartilage and protects against inflammatory degradation when used as a medium
supplement. Journal of Biomedical Materials Research Part A. 2009;91A(3):692-700.
doi:10.1002/jbm.a.32305
85. Elder SH, Mosher ML, Jarquin P, Smith P, Chironis A. Effects of short-duration treatment of
cartilage with punicalagin and genipin and the implications for treatment of osteoarthritis.
Journal of Biomedical Materials Research Part B: Applied Biomaterials. 2021;109(6):818828. doi:10.1002/jbm.b.34747
86. Ayhan E. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for
the knee osteoarthritis. World Journal of Orthopedics. 2014;5(3):351.
doi:10.5312/wjo.v5.i3.351
87. Iannitti T, Lodi D, Palmieri B. Intra-Articular Injections for the Treatment of Osteoarthritis.
Drugs R D. Published online 2011:15.
88. Nguyen C, Lefèvre-Colau MM, Poiraudeau S, Rannou F. Evidence and recommendations for
use of intra-articular injections for knee osteoarthritis. Annals of Physical and Rehabilitation
Medicine. 2016;59(3):184-189. doi:10.1016/j.rehab.2016.02.008
89. Wu W, Billinghurst RC, Pidoux I, et al. Sites of collagenase cleavage and denaturation of
type II collagen in aging and osteoarthritic articular cartilage and their relationship to the
distribution of matrix metalloproteinase 1 and matrix metalloproteinase 13. Arthritis &
Rheumatism. 2002;46(8):2087-2094. doi:10.1002/art.10428
90. Mäkelä JTA, Rezaeian ZS, Mikkonen S, et al. Site-dependent changes in structure and
function of lapine articular cartilage 4 weeks after anterior cruciate ligament transection.
Osteoarthritis and Cartilage. 2014;22(6):869-878. doi:10.1016/j.joca.2014.04.010
91. Butler MF, Ng YF, Pudney PDA. Mechanism and kinetics of the crosslinking reaction
between biopolymers containing primary amine groups and genipin. Journal of Polymer
Science Part A: Polymer Chemistry. 2003;41(24):3941-3953. doi:10.1002/pola.10960
92. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Mono-Iodoacetate-Induced
Histologic Changes in Subchondral Bone and Articular Cartilage of Rat Femorotibial Joints:
An Animal Model of Osteoarthritis. Toxicol Pathol. 2003;31(6):619-624.
doi:10.1080/01926230390241800
93. Kim JE, Song D hyun, Kim SH, Jung Y, Kim SJ. Development and characterization of
various osteoarthritis models for tissue engineering. PLoS One. 2018;13(3).
doi:10.1371/journal.pone.0194288
94. Pitcher T, Sousa-Valente J, Malcangio M. The Monoiodoacetate Model of Osteoarthritis
Pain in the Mouse. J Vis Exp. 2016;(111). doi:10.3791/53746

104

95. Gerwin N, Bendele AM, Glasson S, Carlson CS. The OARSI histopathology initiative –
recommendations for histological assessments of osteoarthritis in the rat. Osteoarthritis and
Cartilage. 2010;18:S24-S34. doi:10.1016/j.joca.2010.05.030
96. Kloefkorn HE, Jacobs BL, Loye AM, Allen KD. Medial meniscus transection in the rat
results in modified ground reaction forces and subsequent development of knee OA.
Osteoarthritis and Cartilage. 2013;21:S67-S68. doi:10.1016/j.joca.2013.02.147
97. Kloefkorn HE, Jacobs BY, Loye AM, Allen KD. Spatiotemporal gait compensations
following medial collateral ligament and medial meniscus injury in the rat: correlating gait
patterns to joint damage. Arthritis Research & Therapy. 2015;17(1):287.
doi:10.1186/s13075-015-0791-2

105

